JP5759894B2 - Medical or medical auxiliary composition comprising zeolite and sericite - Google Patents

Medical or medical auxiliary composition comprising zeolite and sericite Download PDF

Info

Publication number
JP5759894B2
JP5759894B2 JP2011522827A JP2011522827A JP5759894B2 JP 5759894 B2 JP5759894 B2 JP 5759894B2 JP 2011522827 A JP2011522827 A JP 2011522827A JP 2011522827 A JP2011522827 A JP 2011522827A JP 5759894 B2 JP5759894 B2 JP 5759894B2
Authority
JP
Japan
Prior art keywords
preparation
zeolite
sericite
mixture
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011522827A
Other languages
Japanese (ja)
Other versions
JPWO2011007794A1 (en
Inventor
弘子 石塚
弘子 石塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAPAS CO., LTD.
Original Assignee
RAPAS CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RAPAS CO., LTD. filed Critical RAPAS CO., LTD.
Priority to JP2011522827A priority Critical patent/JP5759894B2/en
Publication of JPWO2011007794A1 publication Critical patent/JPWO2011007794A1/en
Application granted granted Critical
Publication of JP5759894B2 publication Critical patent/JP5759894B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Description

本発明は、ゼオライトとセリサイトを配合してなる医療用又は医療補助組成物に関する。   The present invention relates to a medical or medical supplement composition comprising zeolite and sericite.

ゼオライトは有害化学物質、重金属を吸着する、水分を吸着し湿度の調整機能がある、菌の繁殖を抑える、pHの調節機能がある、ウイルスの吸着効果がある、及び遠赤効果があることが知られている。そして、特許文献1中には使い捨ての発泡性洗浄物品中の一成分としてゼオライトが挙げられており、特許文献2中には有効成分の担体としてゼオライトが挙げられている。
セリサイトは、皮膚を保護する機能がある、皮膚の適度な保湿効果がある、及び遠赤効果があることが知られている。そして、特許文献3中に化粧品の充填剤の一成分としてセリサイトが挙げられている。
Zeolite adsorbs toxic chemicals, heavy metals, adsorbs moisture and adjusts humidity, suppresses bacterial growth, adjusts pH, has a virus-adsorbing effect, and has a far-red effect Are known. And in patent document 1, zeolite is mentioned as one component in a disposable foamable washing | cleaning article, and the zeolite is mentioned as patent document 2 as a support | carrier of an active ingredient.
It is known that sericite has a function of protecting the skin, has an appropriate moisturizing effect on the skin, and has a far-red effect. Patent Document 3 mentions sericite as one component of a cosmetic filler.

特表2007−510006Special table 2007-510006 特表2004−538300Special table 2004-538300 特開2005−325121JP 2005-325121 A

本発明の解決しようとする課題は、種々医療領域におけるゼオライト及びセリサイトの有用性を高めることである。   The problem to be solved by the present invention is to increase the usefulness of zeolite and sericite in various medical fields.

本発明は、公知のゼオライト及びセリサイトを配合することにより、相乗効果があることを見出したことを最も主要な特徴とする。つまり、
1.ゼオライトとセリサイトを配合してなる医療用又は医療補助組成物。
2.外用組成物又は経口用組成物である前項1に記載の組成物。
3.セリサイトが、粒子径50μm以下の粒子である前項1または2に記載の組成物。
4.ゼオライトが、粒子径300μm以下の粒子である前項1〜3のいずれか一に記載の組成物。
5.ゼオライトとセリサイトの配合比が、略10〜略90重量%:略90〜略10重量%である前項1〜4のいずれか一に記載の組成物。
6.外用組成物が、噴霧用製剤、練状製剤、液剤、懸濁剤、粉末剤、クリーム剤、エアゾール剤、軟膏剤、リニメント剤、または坐剤である前項2〜5のいずれか一に記載の組成物。
7.外用組成物が、用時調製用組成物である前項2〜5のいずれか一に記載の組成物。
8.経口用組成物が、カプセル製剤、粉末剤、錠剤、懸濁剤、または顆粒剤である前項2〜5のいずれか一に記載の組成物。
9.ゼオライトとセリサイトの総配合量が、組成物中の略50重量%以上である前項1〜8のいずれか一に記載の組成物。
10.前項1〜9のいずれか一に記載の組成物を塗布、配合または吸収させて調製された医薬品、医薬部外品、化粧品または衛生用品。
11.紙、繊維、繊維状物質、不繊布、脱脂綿またはフィルムに塗布または吸収させて調製された前項10に記載の医薬品、医薬部外品、化粧品または衛生用品。
The main feature of the present invention is that it has been found that there is a synergistic effect by blending known zeolite and sericite. That means
1. A medical or medical supplement composition comprising zeolite and sericite.
2. 2. The composition according to item 1, which is an external composition or an oral composition.
3. 3. The composition according to item 1 or 2, wherein the sericite is a particle having a particle size of 50 μm or less.
4). 4. The composition according to any one of items 1 to 3, wherein the zeolite is a particle having a particle diameter of 300 μm or less.
5. 5. The composition according to any one of items 1 to 4, wherein the blending ratio of zeolite and sericite is about 10 to about 90% by weight: about 90 to about 10% by weight.
6). The external composition is a spray preparation, a kneaded preparation, a solution, a suspension, a powder, a cream, an aerosol, an ointment, a liniment, or a suppository, according to any one of items 2 to 5 above. Composition.
7). 6. The composition according to any one of items 2 to 5 above, wherein the composition for external use is a composition for preparation at the time of use.
8). 6. The composition according to any one of items 2 to 5 above, wherein the oral composition is a capsule preparation, powder, tablet, suspension, or granule.
9. 9. The composition according to any one of items 1 to 8, wherein the total amount of zeolite and sericite is about 50% by weight or more in the composition.
10. A pharmaceutical, quasi-drug, cosmetic or hygiene product prepared by applying, blending or absorbing the composition according to any one of the preceding items 1 to 9.
11. 11. The pharmaceutical product, quasi-drug, cosmetic product or hygiene product according to the item 10 prepared by coating or absorbing paper, fiber, fibrous material, non-woven fabric, absorbent cotton or film.

本発明の組成物は、ゼオライト又はセリサイト単独使用に比較して、治療、改善効果において、明確な相乗効果がある。   The composition of the present invention has a clear synergistic effect in treatment and improvement effects compared to the use of zeolite or sericite alone.

エステレーザーによる脱毛処置で、やけど症状のボランティアに本発明組成物を処置した結果の写真。ひざの部位。6月28日の時点で、膝はやけただれていたが、7月4日にはほぼ正常な皮膚にもどった。A photograph of the result of treatment of the composition of the present invention to a volunteer with burn symptoms in hair removal treatment with an esthetic laser. The part of the knee. As of June 28, the knees were burned, but on July 4, they returned to almost normal skin. エステレーザーによる脱毛処置で、やけど症状のボランティアに本発明組成物を処置した結果の写真。背中の部位。6月28日の時点で、背中一面やけただれていたが、7月4日にはほぼ正常な皮膚にもどった。A photograph of the result of treatment of the composition of the present invention to a volunteer with burn symptoms in hair removal treatment with an esthetic laser. The part of the back. As of June 28th, his back was completely burned, but on July 4th he returned to almost normal skin. エステレーザーによる脱毛処置で、やけど症状のボランティアに本発明組成物を処置した結果の写真。へそ周りの部位。6月28日の時点で、へそ周辺が赤くただれていたが、7月4日にはほぼ正常な皮膚にもどった。A photograph of the result of treatment of the composition of the present invention to a volunteer with burn symptoms in hair removal treatment with an esthetic laser. The area around the navel. As of June 28, the area around the navel was red, but on July 4, it returned to almost normal skin.

本発明は、ゼオライトとセリサイトを配合してなる医療用又は医療補助組成物である。
ゼオライト(zeolite)は、結晶中に微細孔を持つアルミノ珪酸塩の総称である。和名は沸石(ふっせき)ともいう。天然に産出する鉱物であり、内部に水が含まれているため加熱すると沸騰しているように見えることから、ギリシャ語のzeo(沸騰する)とlithos(石)を合わせてzeoliteと名付けられた。分子ふるい、イオン交換材、触媒、吸着材として利用され、現在ではさまざまな性質を持つゼオライトが人工的に合成されており、工業的にも重要な物質となっている。例えば、以下のゼオライトが知られている。
The present invention is a medical or medical supplement composition comprising zeolite and sericite.
Zeolite is a generic name for aluminosilicates with fine pores in the crystals. The Japanese name is also called fukuseki. It is a naturally occurring mineral that contains water in it and appears to boil when heated, so the Greek word zeo (boiling) and lithos (stone) are combined to name it zeolite. . Zeolite is used as a molecular sieve, ion-exchange material, catalyst, and adsorbent. At present, zeolites with various properties have been artificially synthesized and are industrially important materials. For example, the following zeolites are known.

amicite
K4Na4[Al8Si8O32]・10H2O、単斜晶系。
アンモニウム白榴石(ammonioleucite)
(NH4)[AlSi2O6]、正方晶系。
方沸石(analcime)
Na[AlSi2O6]・H2O、等軸晶系・正方晶系・斜方晶系・単斜晶系・三斜晶系。
バレル沸石(barrerite)
Na2[Al2Si7O18]・6H2O、斜方晶系。
bellbergite
(K,Ba,Sr)2Sr2Ca2(Ca,Na)4[Al18Si18O72]・30H2O、六方晶系。
bikitaite
Li[AlSi2O6]・H2O、単斜晶系・三斜晶系。
boggsite
Ca8Na3[Al19Si77O192]・70H2O、斜方晶系。
amicite
K 4 Na 4 [Al 8 Si 8 O 32 ] · 10H 2 O, monoclinic system.
Ammonium leucite (ammonioleucite)
(NH 4 ) [AlSi 2 O 6 ], tetragonal system.
Anorcime
Na [AlSi 2 O 6 ] / H 2 O, equiaxed, tetragonal, orthorhombic, monoclinic, triclinic.
Barrerite
Na 2 [Al 2 Si 7 O 18 ] · 6H 2 O, orthorhombic.
bellbergite
(K, Ba, Sr) 2 Sr 2 Ca 2 (Ca, Na) 4 [Al 18 Si 18 O 72 ] .30H 2 O, hexagonal system.
bikitaite
Li [AlSi 2 O 6 ] / H 2 O, monoclinic and triclinic.
boggsite
Ca 8 Na 3 [Al 19 Si 77 O 192 ] / 70H 2 O, orthorhombic.

brewsterite(系列名)
(Sr,Ba)2[Al4Si12O32]・10H2O、単斜晶系・三斜晶系。
brewsterite-Sr
brewsterite-Ba
菱沸石(chabazite)(系列名)
(Ca0.5,Na,K)4[Al4Si8O24]・12H2O、三方晶系・三斜晶系。
灰菱沸石(chabazite-Ca)
ソーダ菱沸石(chabazite-Na)
カリ菱沸石(chabazite-K)
chiavennite
CaMn[Be2Si5O13(OH)2]・2H2O、斜方晶系。
brewsterite (series name)
(Sr, Ba) 2 [Al 4 Si 12 O 32 ] · 10H 2 O, monoclinic / triclinic.
brewsterite-Sr
brewsterite-Ba
Chabazite (series name)
(Ca 0.5 , Na, K) 4 [Al 4 Si 8 O 24 ] · 12H 2 O, trigonal and triclinic.
Chabazite-Ca
Soda rhodolite (chabazite-Na)
Potassium chabazite-K
chiavennite
CaMn [Be 2 Si 5 O 13 (OH) 2 ] · 2H 2 O, orthorhombic.

斜プチロル沸石(clinoptilolite)(系列名)
(Na,K,Ca0.5,Sr0.5,Ba0.5,Mg0.5)6[Al6Si30O72]・〜20H2O、単斜晶系。
カリ斜プチロル沸石(clinoptilolite-K)
ソーダ斜プチロル沸石(clinoptilolite-Na)
灰斜プチロル沸石(clinoptilolite-Ca)
コウルス沸石(cowlesite)
Ca[Al2Si3O10]・5.3H2O、斜方晶系。
ダキアルディ沸石(dachiardite)(系列名)
(Ca0.5,Na,K)4-5[Al4-5Si20-19O48]・13H2O、単斜晶系。
灰ダキアルディ沸石(dachiardite-Ca)
ソーダダキアルディ沸石(dachiardite-Na)
エディントン沸石(edingtonite)
Ba[Al2Si3O10]・4H2O、斜方晶系・正方晶系。
剥沸石(epistilbite)
(Ca,Na2)[Al2Si4O12]・4H2O、単斜晶系・三斜晶系。
Clinoptilolite (series name)
(Na, K, Ca 0.5 , Sr 0.5 , Ba 0.5 , Mg 0.5 ) 6 [Al 6 Si 30 O 72 ] · ˜20H 2 O, monoclinic system.
Potassium clinoptilolite (clinoptilolite-K)
Soda clinoptilolite (clinoptilolite-Na)
Clinoptilolite-Ca
Cowlesite
Ca [Al 2 Si 3 O 10 ] · 5.3H 2 O, orthorhombic system.
Dachiardite (series name)
(Ca 0.5 , Na, K) 4-5 [Al 4-5 Si 20-19 O 48 ] · 13H 2 O, monoclinic system.
Ash dachiardite (dachiardite-Ca)
Soda-Dakiardite (dachiardite-Na)
Edingtonite
Ba [Al 2 Si 3 O 10 ] · 4H 2 O, orthorhombic and tetragonal.
Epistilbite
(Ca, Na 2 ) [Al 2 Si 4 O 12 ] · 4H 2 O, monoclinic and triclinic.

エリオン沸石(erionite)(系列名)
K2(Na,Ca0.5)8[Al10Si26O72]・30H2O、六方晶系。
ソーダエリオン沸石(erionite-Na)
カリエリオン沸石(erionite-K)
灰エリオン沸石(erionite-Ca)
faujasite(系列名)
(Na,Ca0.5,Mg0.5,K)x[AlxSi12-xO24]・16H2O、等軸晶系。
faujasite-Na
faujasite-Ca
faujasite-Mg
Erionite (series name)
K 2 (Na, Ca 0.5 ) 8 [Al 10 Si 26 O 72 ] · 30H 2 O, hexagonal system.
Soda erionite (erionite-Na)
Cary Elionite (erionite-K)
Erionite-Ca
faujasite (series name)
(Na, Ca 0.5 , Mg 0.5 , K) x [Al x Si 12-x O 24 ] · 16H 2 O, equiaxed system.
faujasite-Na
faujasite-Ca
faujasite-Mg

フェリエ沸石(ferrierite)(系列名)
(K,Na,Mg0.5,Ca0.5)6[Al6Si30O72]・18H2O、斜方晶系・単斜晶系。
苦土フェリエ沸石(ferrierite-Mg)
カリフェリエ沸石(ferrierite-K)
ソーダフェリエ沸石(ferrierite-Na)
ガロン沸石(garronite)
NaCa2.5[Al6Si10O32]・14H2O、正方晶系・斜方晶系。
gaultite
Na4[Zn2Si7O18]・5H2O、斜方晶系。
ギスモンド沸石(gismondine)
Ca[Al2Si2O8]・4.5H2O、単斜晶系。
Ferrierite (series name)
(K, Na, Mg 0.5 , Ca 0.5 ) 6 [Al 6 Si 30 O 72 ] · 18H 2 O, orthorhombic and monoclinic.
Ferrierite-Mg
Califerierite (ferrierite-K)
Soda ferrierite (ferrierite-Na)
Garronite
NaCa 2.5 [Al 6 Si 10 O 32 ], 14H 2 O, tetragonal and orthorhombic.
gaultite
Na 4 [Zn 2 Si 7 O 18 ] ・ 5H 2 O, orthorhombic.
Gismondine
Ca [Al 2 Si 2 O 8 ] · 4.5H 2 O, monoclinic system.

グメリン沸石(gmelinite)(系列名)
(Na2,Ca,K2)4[Al8Si16O48]・22H2O、六方晶系。
ソーダグメリン沸石(gmelinite-Na)
灰グメリン沸石(gmelinite-Ca)
カリグメリン沸石(gmelinite-K)
ゴビンス沸石(gobbinsite)
Na5[Al5Si11O32]・12H2O、斜方晶系。
ゴナルド沸石(gonnardite)
(Na,Ca)6-8[(Al,Si)20O40]・12H2O、正方晶系。
goosecreekite
Ca[Al2Si6O16]・5H2O、単斜晶系。
gottardiite
Na3Mg3Ca5[Al19Si117O272]・93H2O、斜方晶系。
重土十字沸石(harmotome)
(Ba0.5,Ca0.5,K,Na)5[Al5Si11O32]・12H2O、単斜晶系。
Gmelinite (series name)
(Na 2 , Ca, K 2 ) 4 [Al 8 Si 16 O 48 ] · 22H 2 O, hexagonal system.
Soda gmelinite (gmelinite-Na)
Ash gmelinite-Ca
Caligmelinite (gmelinite-K)
Gobbinsite
Na 5 [Al 5 Si 11 O 32 ] · 12H 2 O, orthorhombic.
Gonnardite
(Na, Ca) 6-8 [(Al, Si) 20 O 40 ] .12H 2 O, tetragonal system.
goosecreekite
Ca [Al 2 Si 6 O 16 ] · 5H 2 O, monoclinic system.
gottardiite
Na 3 Mg 3 Ca 5 [Al 19 Si 117 O 272 ] / 93H 2 O, orthorhombic.
Heavy soil zeolitic (harmotome)
(Ba 0.5 , Ca 0.5 , K, Na) 5 [Al 5 Si 11 O 32 ] · 12H 2 O, monoclinic system.

輝沸石(heulandite)(系列名)
(Ca0.5,Sr0.5,Ba0.5,Mg0.5,Na,K)9[Al9Si27O72]・〜24H2O、単斜晶系。
灰輝沸石(heulandite-Ca)
ストロンチウム輝沸石(heulandite-Sr)
ソーダ輝沸石(heulandite-Na)
カリ輝沸石(heulandite-K)
hsianghualite
Li2Ca3[Be3Si3O12]F2、等軸晶系。
kalborsite
K6[Al4Si6O20]B(OH)4Cl、正方晶系。
Heulandite (series name)
(Ca 0.5 , Sr 0.5 , Ba 0.5 , Mg 0.5 , Na, K) 9 [Al 9 Si 27 O 72 ] · -24H 2 O, monoclinic system.
Heulandite-Ca
Strontium pyroxenite (heulandite-Sr)
Soda pyrolite (heulandite-Na)
Potassium pyroxenite (heulandite-K)
hsianghualite
Li 2 Ca 3 [Be 3 Si 3 O 12 ] F 2 , equiaxed system.
kalborsite
K 6 [Al 4 Si 6 O 20 ] B (OH) 4 Cl, tetragonal system.

濁沸石(laumontite)
Ca4[Al8Si16O48]・18H2O、単斜晶系。
白榴石(leucite)
K[AlSi2O6]、正方晶系。
レビ沸石(levyne)(系列名)
(Ca0.5,Na,K)6[Al6Si12O36]・〜17H2O、三方晶系。
灰レビ沸石(levyne-Ca)
ソーダレビ沸石(levyne-Na)
Laumontite
Ca 4 [Al 8 Si 16 O 48 ] • 18H 2 O, monoclinic system.
Leucite
K [AlSi 2 O 6 ], tetragonal system.
Levyne (series name)
(Ca 0.5 , Na, K) 6 [Al 6 Si 12 O 36 ] · ˜17H 2 O, trigonal system.
Asylite (levyne-Ca)
Sodalevite (levyne-Na)

lovdarite
K4Na12[Be8Si28O72]・18H2O、斜方晶系。
maricopaite
(Pb7Ca2)[Al12Si36(O,OH)100]・n(H2O,OH), n〜32、斜方晶系。
mazzite
(Mg2.5K2Ca1.5)[Al10Si26O72]・30H2O、六方晶系。
merlinoite
K5Ca2[Al9Si23O64]・22H2O、斜方晶系。
中沸石(mesolite)
Na16Ca16[Al48Si72O240]・64H2O、斜方晶系。
montesommaite
K9[Al9Si23O64]・10H2O、斜方晶系。
mordenite
(Na2,Ca,K2)4[Al8Si40O96]・28H2O、斜方晶系。
lovdarite
K 4 Na 12 [Be 8 Si 28 O 72 ] ・ 18H 2 O, orthorhombic system.
maricopaite
(Pb 7 Ca 2 ) [Al 12 Si 36 (O, OH) 100 ] · n (H 2 O, OH), n to 32, orthorhombic system.
mazzite
(Mg 2.5 K 2 Ca 1.5 ) [Al 10 Si 26 O 72 ] · 30H 2 O, hexagonal system.
merlinoite
K 5 Ca 2 [Al 9 Si 23 O 64 ] · 22H 2 O, orthorhombic.
Mesolite
Na 16 Ca 16 [Al 48 Si 72 O 240 ] · 64H 2 O, orthorhombic system.
montesommaite
K 9 [Al 9 Si 23 O 64 ] · 10H 2 O, orthorhombic system.
mordenite
(Na 2 , Ca, K 2 ) 4 [Al 8 Si 40 O 96 ] · 28H 2 O, orthorhombic system.

mutinaite
Na3Ca4[Al11Si85O192]・60H2O、斜方晶系。
ソーダ沸石(natrolite)
Na2[Al2Si3O10]・2H2O、斜方晶系。
offretite
CaKMg[Al5Si13O36]・16H2O、六方晶系。
pahasapaite
(Ca5.5Li3.6K1.2Na0.2)Li8[Be24P24O96]・38H2O、等軸晶系。
partheite
Ca2[Al4Si4O15(OH)2]・4H2O、単斜晶系。
paulingite(系列名)
(K,Ca0.5,Na,Ba0.5)10[Al10Si32O84]・27-44H2O、等軸晶系。
paulingite-K
paulingite-Ca
mutinaite
Na 3 Ca 4 [Al 11 Si 85 O 192 ] / 60H 2 O, orthorhombic.
Sodaite (natrolite)
Na 2 [Al 2 Si 3 O 10 ] · 2H 2 O, orthorhombic.
offretite
CaKMg [Al 5 Si 13 O 36 ] · 16H 2 O, hexagonal system.
pahasapaite
(Ca 5.5 Li 3.6 K 1.2 Na 0.2 ) Li 8 [Be 24 P 24 O 96 ] · 38H 2 O, equiaxed system.
partheite
Ca 2 [Al 4 Si 4 O 15 (OH) 2 ] · 4H 2 O, monoclinic system.
paulingite (series name)
(K, Ca 0.5 , Na, Ba 0.5 ) 10 [Al 10 Si 32 O 84 ] / 27-44H 2 O, equiaxed system.
paulingite-K
paulingite-Ca

perlialite
K9Na(Ca,Sr)[Al12Si24O72]・15H2O、六方晶系。
十字沸石(phillipsite)(系列名)
(K,Na,Ca0.5,Ba0.5)x[AlxSi16-xO32]・12H2O、単斜晶系。
ソーダ十字沸石(phillipsite-Na)
カリ十字沸石(phillipsite-K)
灰十字沸石(phillipsite-Ca)
ポルクス石(pollucite)
(Cs,Na)[AlSi2O6]・nH2O,where (Cs+n)=1、等軸晶系。
perlialite
K 9 Na (Ca, Sr) [Al 12 Si 24 O 72 ] .15H 2 O, hexagonal system.
Phillipsite (series name)
(K, Na, Ca 0.5 , Ba 0.5 ) x [Al x Si 16-x O 32 ] · 12H 2 O, monoclinic system.
Soda zeolitic (phillipsite-Na)
Potash cross-stone (phillipsite-K)
Ashesite (phillipsite-Ca)
Pollucite
(Cs, Na) [AlSi 2 O 6 ] · nH 2 O, where (Cs + n) = 1, equiaxed system.

roggianite
Ca2[Be(OH)2Al2Si4O13]・<2.5H2O、正方晶系。
スコレス沸石(scolecite)
Ca[Al2Si3O10]・3H2O、単斜晶系。
ステラ沸石(stellerite)
Ca[Al2Si7O18]・7H2O、斜方晶系。
束沸石(stilbite)(系列名)
(Ca0.5,Na,K)9[Al9Si27O72]・28H2O、単斜晶系。
灰束沸石(stilbite-Ca)
ソーダ束沸石(stilbite-Na)
roggianite
Ca 2 [Be (OH) 2 Al 2 Si 4 O 13 ] ・ <2.5H 2 O, tetragonal system.
Scolecite
Ca [Al 2 Si 3 O 10 ] · 3H 2 O, monoclinic system.
Stellarite
Ca [Al 2 Si 7 O 18 ] · 7H 2 O, orthorhombic.
Stilbite (series name)
(Ca 0.5 , Na, K) 9 [Al 9 Si 27 O 72 ] · 28H 2 O, monoclinic system.
Stilbite-Ca
Soda bite (stilbite-Na)

terranovaite
NaCa[Al3Si17O40]・>7H2O、斜方晶系。
トムソン沸石(thomsonite)
Ca2Na[Al5Si5O20]・6H2O、斜方晶系。
tschernichite
Ca[Al2Si6O16]・〜8H2O、正方晶系。
tschortnerite
Ca4(K2,Ca,Sr,Ba)3Cu3(OH)8[Al12Si12O48]・nH2O, n〜20、等軸晶系。
ワイラケ沸石(wairakite)
Ca[Al2Si4O12]・2H2O、単斜晶系・正方晶系。
weinebeneite
Ca[Be3(PO4)2(OH)2]・4H2O、単斜晶系。
willhendersonite
KxCa(1.5-0.5x)[Al3Si3O12]・5H2O, where 0<x<1、三斜晶系。
湯河原沸石(yugawaralite)
Ca[Al2Si6O16]・4H2O、単斜晶系・三斜晶系。
terranovaite
NaCa [Al 3 Si 17 O 40 ],> 7H 2 O, orthorhombic.
Thomsonite
Ca 2 Na [Al 5 Si 5 O 20 ] · 6H 2 O, orthorhombic system.
tschernichite
Ca [Al 2 Si 6 O 16 ] · ~ 8H 2 O, tetragonal system.
tschortnerite
Ca 4 (K 2, Ca, Sr, Ba) 3 Cu 3 (OH) 8 [Al 12 Si 12 O 48] · nH 2 O, n~20, isometric system.
Wairakite
Ca [Al 2 Si 4 O 12 ] · 2H 2 O, monoclinic and tetragonal.
weinebeneite
Ca [Be 3 (PO 4 ) 2 (OH) 2 ] · 4H 2 O, monoclinic system.
willhendersonite
K x Ca (1.5-0.5x) [Al 3 Si 3 O 12 ] ・ 5H 2 O, where 0 <x <1, triclinic system.
Yugawaraite
Ca [Al 2 Si 6 O 16 ] ・ 4H 2 O, monoclinic and triclinic.

本発明の実施例で使用したゼオライトは、(株)イズカ製 イズカライト63(表3)、サンゼオライト工業製 サンゼオライトSSであるが、特に限定されるものでない。好適なゼオライト結晶としては、クリノプチロライト(表5)〔斜プチロル沸石(clinoptilolite)(系列名) (Na,K,Ca0.5,Sr0.5,Ba0.5,Mg0.5)6[Al6Si30O72]・〜20H2O、単斜晶系、カリ斜プチロル沸石(clinoptilolite-K)、ソーダ斜プチロル沸石(clinoptilolite-Na)、灰斜プチロル沸石(clinoptilolite-Ca)〕とモルデナイト〔(Ca,Na2,K2)Al2Si10O24・7H2O〕が挙げられる。使用するゼオライトは天然が好ましい。ゼオライトの純度は略70%以上、さらに好ましいのは略80%以上、さらに好ましいのは略90%以上である。ゼオライトは、粉砕、精製して使用されるが、粒子径は300μm以下、好ましくは200μm以下、さらに好ましいのは100μm以下のものが使用される。塩素置換容量は120meq/100g以上、さらに好ましいのは130 meq/100g以上、一般的には120〜180meq/100gを使うことができる。pHは6〜9より好ましいのは6.5〜8である。Zeolite used in Examples of the present invention is Izukalite 63 (Table 3) manufactured by Izuka Co., Ltd. and Sun Zeolite SS manufactured by Sun Zeolite Industry, but is not particularly limited. Suitable zeolite crystals include clinoptilolite (Table 5) [clinoptilolite (series name) (Na, K, Ca 0.5 , Sr 0.5 , Ba 0.5 , Mg 0.5 ) 6 [Al 6 Si 30 O 72 ]-20H 2 O, monoclinic, potash clinoptilolite (clinoptilolite-K), soda clinoptilolite (clinoptilolite-Na), clinoptilolite (clinoptilolite-Ca)] and mordenite [(Ca, Na 2 , K 2 ) Al 2 Si 10 O 24 · 7H 2 O]. The zeolite used is preferably natural. The purity of the zeolite is about 70% or more, more preferably about 80% or more, and more preferably about 90% or more. Zeolite is used after being pulverized and refined, and those having a particle size of 300 μm or less, preferably 200 μm or less, and more preferably 100 μm or less are used. The chlorine replacement capacity is 120 meq / 100 g or more, more preferably 130 meq / 100 g or more, and generally 120 to 180 meq / 100 g. The pH is more preferably 6.5-8, more preferably 6-9.

本発明において、セリサイトとは、絹雲母(きぬうんも、sericite)ともいい、層状珪酸塩鉱物である白雲母の細粒なもので、粘土鉱物の一種である。
化学組成は白雲母と同じKAl2AlSi3O10(OH)2であり、単斜晶系である。大規模な絹雲母鉱床は、酸性または中性の火山岩類が熱水変質を被って形成されることが多く、絹糸状もしくは粉末状の塊として産出する。主に、長石が変質し、鉄、マグネシウム、カルシウム等が溶脱して形成される。日本では、戦後の復興期に様々な鉱山がセリサイトの採掘を行ったが、現在でも採掘を続けているのは愛知県北設楽郡東栄町にある粟代鉱山と、島根県出雲市上島町にある鍋山鉱山のみである。粟代鉱山では、三信鉱工株式会社が「三信マイカ」という商品名で精製後のセリサイトを販売しており、高純度かつ不純物が少ない特徴により、主に化粧品や薬品原料として用いられている。また、鍋山鉱山では、斐川礦業株式会社により「斐川マイカZ20」という商品名で販売が行われており、工業原料から化粧品原料まで幅広い用途で使用されている。一般には、化粧品のファンデーションやセラミックの素材として用いられている。また、耐熱性のある潤滑材として使用。微粉砕したものは、プラスチックなどの強化材としても使用されている。
In the present invention, sericite is also called sericite and is a fine grain of muscovite, a layered silicate mineral, and is a kind of clay mineral.
The chemical composition is KAl 2 AlSi 3 O 10 (OH) 2, which is the same as muscovite, and is monoclinic. Large-scale sericite deposits are often formed by hydrothermal alteration of acidic or neutral volcanic rocks, and are produced as silky or powdery masses. Mainly, feldspar is altered and iron, magnesium, calcium, etc. are leached. In Japan, various mines mined sericite during the post-war reconstruction period, but the mining is still ongoing in the Toshiro Mine in Kitasakura-gun, Aichi Prefecture and Kamijima Town, Izumo City, Shimane Prefecture. There is only one Nabeyama mine. In the Bandai Mine, Sanshin Mining Co., Ltd. sells purified sericite under the product name “Sanshin Mica”, which is mainly used as a raw material for cosmetics and chemicals due to its high purity and low impurities. . The Nabeyama Mine is sold under the trade name “Yodogawa Mica Z20” by Yodogawa Sangyo Co., Ltd. and is used in a wide range of applications from industrial raw materials to cosmetic raw materials. In general, it is used as a foundation for cosmetics or as a ceramic material. Also used as a heat-resistant lubricant. The finely pulverized product is also used as a reinforcing material such as plastic.

本発明の実施例で使用したセリサイトは斐川礦業の斐川マイカZ20(表4)が好適に例示され、それ以外では三信鉱工(株)、三信マイカFSE、三信マイカFSNなどが有る。セリサイトは50μm以下、好ましいのは30μm以下、さらに好ましいのは10μm以下の粒子径のものが好適に使用される。天然物が好ましい。pHは、4〜9.5が一般的である。   The sericite used in the examples of the present invention is preferably exemplified by Yodogawa Mika Z20 (Table 4) from Yodogawa Industries, and other companies include Sanshin Mining Co., Ltd., Sanshin Mica FSE, and Sanshin Mica FSN. Sericite having a particle size of 50 μm or less, preferably 30 μm or less, and more preferably 10 μm or less is preferably used. Natural products are preferred. The pH is generally 4 to 9.5.

本発明のゼオライトとセリサイトの組成物は、外用又は経口製剤として使用可能である。そして、その配合比は、一般的には略10〜略90重量%:略90〜略10重量%である。略とは、この範囲から少々はずれていても、対効果との考量により、配合を数%増減可能であり、均等幅を意味する。以下同様である。ゼオライトとセリサイトの総配合量は、組成物中の略50重量%以上である。その他の配合剤としては、乳化剤、賦形剤、安定剤、水、油成分等が目的に応じて公知の成分から選択可能である。外用組成物の場合、ゼオライトとセリサイトの配合は、略10:略90〜略50:略50であり、セリサイトが必須の主成分となる。経口用組成物の場合は、ゼオライトとセリサイトの配合は、略90:略10〜略50:略50であり、ゼオライトが必須の主成分となる。   The composition of zeolite and sericite of the present invention can be used as an external or oral preparation. The blending ratio is generally about 10 to about 90% by weight: about 90 to about 10% by weight. The term “substantially” means that even if it is slightly deviated from this range, the composition can be increased or decreased by several percent depending on the consideration of the counter effect, and means a uniform width. The same applies hereinafter. The total amount of zeolite and sericite is approximately 50% by weight or more in the composition. As other compounding agents, emulsifiers, excipients, stabilizers, water, oil components and the like can be selected from known components according to the purpose. In the case of the composition for external use, the blend of zeolite and sericite is about 10: about 90 to about 50: about 50, and sericite is an essential main component. In the case of an oral composition, the composition of zeolite and sericite is approximately 90: approximately 10 to approximately 50: approximately 50, and zeolite is an essential main component.

外用組成物は、外用医薬品、外用医薬部外品、化粧品などを含む。剤形は制限はないが、例えば、噴霧用製剤、練状製剤、液剤、懸濁剤、クリーム剤、エアゾール剤、軟膏剤、リニメント剤、または坐剤等が挙げられる。 The composition for external use includes external medicines, quasi-drugs for external use, cosmetics and the like. The dosage form is not limited, and examples thereof include spray preparations, kneaded preparations, solutions, suspensions, creams, aerosols, ointments, liniments, and suppositories.

本発明の外用組成物の一実施態様は、ゼオライトとセリサイトの混合品を、水と混合して調製される。水との配合比は、製剤の硬さ、用途とも関係するが、一般的には混合粉体:水=100:30〜100:300である。使いやすさと外用剤としての効果の観点から、特に、練り状製剤の場合、好適な水との配合比は、混合粉体:水=100:40〜100:80、好適には100:50〜100:75、より好適には100:60〜100:75、さらに好適には100:65〜100:70である。水は、中性のものが好適である。水には、乳化のために、油脂成分、界面活性剤などを含んでいてもよく、水の中のその他の成分は略30重量%以下が好適である。これ以上含有していては、製剤的に皮膚との親和性や、ゼオライト、セリサイトの本来持っている機能が、油成分や有機化学物質で阻害されるなどで効果がおちる。   One embodiment of the composition for external use of the present invention is prepared by mixing a mixture of zeolite and sericite with water. The mixing ratio with water is related to the hardness and use of the preparation, but is generally mixed powder: water = 100: 30 to 100: 300. From the viewpoint of ease of use and effect as an external preparation, particularly in the case of a kneaded preparation, the mixing ratio with water is preferably a mixed powder: water = 100: 40 to 100: 80, preferably 100: 50 to 100: 75, more preferably 100: 60 to 100: 75, and even more preferably 100: 65 to 100: 70. The water is preferably neutral. For emulsification, water may contain an oil and fat component, a surfactant and the like, and the other components in water are preferably about 30% by weight or less. If it is contained more than this, the effect on the skin will be reduced, for example, the affinity with the skin and the functions inherent to zeolite and sericite are inhibited by oil components and organic chemicals.

本発明の外用組成物は、水等との混合製剤である練り状製剤またはペースト状製剤を例えばそのまま塗ることにより使用することができる。また、紙、繊維状物質、不織布、脱脂綿またはフィルム等の表面に外用組成物を塗布したものを使用することもできる。練状製剤を塗布した場合は、製剤は、乾燥を防ぐため水分の蒸散を防ぐ手段を講じることが好適である。ただし、乾燥した組成物には効果が無いということでは無い。無論、練状製剤をチューブ等の密閉容器の中に充填し、用時、該容器から取り出し、紙、繊維、繊維状物質、不織布、脱脂綿又はフィルムの表面に塗布してもよい。本発明の外用組成物は、水等との混合製剤を、比較的水の割合の多い液状製剤とし、そのまま或は噴霧剤としてつかってもよい。さらに、本発明の外用組成物は、混合粉末そのままを、噴霧する剤型でもよい。噴霧する場合、対象が予め水等で湿らせておく必要があり、或は、傷口等のように、体液が十分に漏出している状態ではそのまま粉末を対象に噴霧塗布可能である。さらに、本発明の外用組成物は、各種皮膚・毛髪等に使用する液状・練状製剤に配合若しくは用時配合可の製剤としてもよい。   The composition for external use of the present invention can be used, for example, by applying a kneaded preparation or a paste preparation which is a mixed preparation with water or the like as it is. Moreover, what coated the composition for external use on the surface, such as paper, a fibrous material, a nonwoven fabric, absorbent cotton, or a film, can also be used. When a kneaded preparation is applied, it is preferable to take measures to prevent moisture from evaporating in order to prevent the preparation from drying. However, this does not mean that the dried composition is ineffective. Of course, the kneaded preparation may be filled in a closed container such as a tube, taken out from the container at the time of use, and applied to the surface of paper, fiber, fibrous substance, nonwoven fabric, absorbent cotton or film. In the composition for external use of the present invention, a mixed preparation with water or the like may be used as a liquid preparation with a relatively high proportion of water, or as a spray. Further, the composition for external use of the present invention may be in a dosage form in which the mixed powder is sprayed as it is. When spraying, the object needs to be previously moistened with water or the like, or the powder can be spray-applied to the object as it is in a state where body fluid is sufficiently leaked, such as a wound. Furthermore, the composition for external use of the present invention may be formulated into a liquid / kneaded preparation used for various skins, hairs, etc., or a preparation that can be mixed at the time of use.

本発明の経口用組成物は、例えば、カプセル製剤、粉末剤、錠剤、懸濁剤、顆粒剤等が例示される。カプセル剤は、カプセル内に混合粉末を包含させ、製剤化できるし、もちろん賦形剤を使用しても良い。粉末剤は、ゼオライトとセリサイトの混合粉末をそのまま製剤化可能であり、懸濁剤では、比較的水の配合割合の多い製剤によって、経口可能な懸濁製剤を調製可能である。経口摂取の場合、粉末のまま水と一緒に摂取してもよいし、他の食物と一緒に摂取してもよく、あるいは公知のふりかけ成分に本発明製剤の粉末を配合させることも可能である。
本発明の経口用組成物は、食品添加剤、飼料添加剤として使用できる。たとえば、食品や飼料への添加が容易な粉末添加剤、練状添加剤が挙げられる。
Examples of the oral composition of the present invention include capsule preparations, powders, tablets, suspensions, granules and the like. Capsules can be formulated by including mixed powders in capsules, and of course, excipients may be used. As a powder, a mixed powder of zeolite and sericite can be formulated as it is, and as a suspension, a suspension preparation that can be orally prepared can be prepared by a preparation with a relatively large proportion of water. In the case of oral ingestion, the powder may be ingested with water, ingested with other foods, or the powder of the preparation of the present invention can be added to a known sprinkling ingredient. .
The oral composition of the present invention can be used as a food additive or a feed additive. For example, powder additives and kneaded additives that can be easily added to foods and feeds are included.

本発明のゼオライトとセリサイトの組成物は、以下のような用途に効果的な相乗効果が確認された。外用適用としては、火傷皮膚疾患、汗疹等による皮膚のかゆみ・ただれ・痛み、アトピー性皮膚炎、切り傷、掻き傷、爪はげ、炎症疾患、日焼け炎症措置、肉離れ、筋肉痛、打撲、打ち身、捻挫、アイシング代替、水虫、蕁麻疹、気管支炎、喘息、口内炎、歯周病、癌性疼痛等が好適に例示できる。これらは、粉末或は練り状物をそのまま或はシート状の物や台状の物に塗布して、患部に適用して使用される。効果は、30分から1時間で発揮されるが、火傷のヒリヒリした痛みは塗って数分で治まり、皮膚の痒みも塗って数分で無くなり、肉離れや、筋肉の炎症の熱や痛みが数分で無くなる。このように直接的知覚による痛み、痒み、熱などには即効性もある。また軽度のものでは、塗って数十秒から1分で痒みや痛みが無くなった事例もある。一日一回から数回製剤の渇き状態により交換すればよい。ただし乾いたから効果が無くなるものでは無い。数日で完治する。   The composition of zeolite and sericite of the present invention was confirmed to have a synergistic effect effective for the following uses. For external application, burn skin disease, itching / sagging / pain of skin due to eczema, atopic dermatitis, cuts, scratches, nail baldness, inflammatory disease, sunburn inflammation measures, flesh, muscle pain, bruise, bruise, sprain Suitable examples include icing substitute, athlete's foot, urticaria, bronchitis, asthma, stomatitis, periodontal disease, and cancer pain. These are used by applying a powder or a kneaded product as it is or by applying it to a sheet or a table and applying it to an affected area. The effect is demonstrated in 30 minutes to 1 hour, but the burns and soreness that heals are cured in a few minutes, and the itchiness of the skin disappears in a few minutes. It will disappear. In this way, pain, itching, heat, etc. due to direct perception have immediate effects. For mild cases, there are cases where itching and pain disappeared after tens of seconds to one minute after application. It may be changed once to several times a day depending on the thirst of the preparation. However, the effect is not lost because it dries. Complete cure in a few days.

経口適用としては、気管支炎、喘息、胃潰瘍、十二指腸潰瘍、胃炎、口内炎、慢性胃炎、歯周病、慢性肝臓病、疲労倦怠感の解消、花粉症、口臭症、癌等が好適に例示できる。これらは、粉末をそのまま或は他の食物と併用して、摂取される。但し、口内炎、歯周病、歯茎の出血等では、練り状製剤を患部に直接適用して使用される。又は懸濁液を口に含む。効果は、30分から1時間で発揮されるが、一日一回から数回摂取すればよい。多くは、数日から10日前後で完治する。   Preferred examples of oral application include bronchitis, asthma, gastric ulcer, duodenal ulcer, gastritis, stomatitis, chronic gastritis, periodontal disease, chronic liver disease, elimination of fatigue fatigue, hay fever, halitosis, cancer and the like. These are taken with the powder as it is or in combination with other foods. However, for stomatitis, periodontal disease, gum bleeding, etc., the paste-like preparation is applied directly to the affected area. Or include the suspension in the mouth. The effect is exhibited in 30 minutes to 1 hour, but it may be taken once to several times a day. Many cure completely in a few days to around 10 days.

本発明はまた、上記のゼオライトとセリサイトの組成物を塗布、配合または吸収させて調製された医薬品、医薬部外品、化粧品または衛生用品に関する。
医薬部外品には、口中清涼剤、育毛剤、除毛剤、染毛剤、生理処理用品、洗浄綿、健胃薬、口腔咽喉薬、殺菌消毒用薬、あせも・ただれ用剤等が含まれる。
化粧品には、シャンプー、リンス、化粧水、クリーム類、髭剃り用剤、日焼け止め剤、薬用石鹸等が含まれる。
衛生用品には、オムツ、トイレットペーパー、ティッシュ、パッド、水虫パッド、傷口パッド、耳掻き用綿棒、エステ用品、シーツ、枕カバー等が含まれる。
本発明の組成物を予め塗布、配合または吸収させて製品を調製すれば皮膚に優しい皮膚疾患に好適な製品の提供が可能である。もちろん化粧品、パックなど美容製品としても肌荒れ、肌のトラブルなどに効果のある皮膚に好適な製品の提供も可能である。
The present invention also relates to a pharmaceutical, a quasi-drug, a cosmetic or a hygiene product prepared by applying, blending or absorbing the above-described zeolite and sericite composition.
Quasi-drugs include mouth fresheners, hair restorers, hair removers, hair dyes, sanitary treatments, cleansing cotton, stomachic medicines, oral and throat medicines, bactericides / disinfectants, skin reptiles and soups, etc. .
Cosmetics include shampoos, rinses, lotions, creams, shaving agents, sunscreens, medicated soaps, and the like.
Hygiene products include diapers, toilet paper, tissues, pads, athlete's foot pads, wound pads, earpick swabs, beauty supplies, sheets, pillowcases, and the like.
If a product is prepared by previously applying, blending or absorbing the composition of the present invention, a product suitable for skin-friendly skin diseases can be provided. Of course, it is also possible to provide a product suitable for skin that is effective for rough skin, skin troubles, etc. as beauty products such as cosmetics and packs.

本発明のゼオライトとセリサイトの組成物は、他の各種薬剤と予め配合して外用組成物としてもよいし、用時調製用組成物としてもよい。たとえば、皮膚・毛髪処理用液状製剤若しくは練り状製剤との配合剤若しくは用時配合剤とすることができる。例えば、染毛剤、パーマ液、髭剃り剤との配合が挙げられ、染毛剤、パーマ液またはひげ剃り剤等に対して2〜10重量%程度のゼオライトとセリサイトの組成物が配合される。配合は、予め配合された製剤を調製してもよいが、用時配合剤(キット製剤)としてもよい。染毛剤、パーマ液、ひげ剃り剤等への配合により、染毛、パーマ、ひげ剃り等の処理が完了した後も、痒み、肌荒れ、ただれ、痛み、アレルギー症状などがおこらず安心して毛染め・パーマ・ひげ剃りが行える。   The composition of zeolite and sericite of the present invention may be blended in advance with other various drugs to form an external composition, or a composition for preparation at the time of use. For example, it can be a compounding agent with a liquid preparation for skin / hair treatment or a kneaded preparation, or a compounding agent at the time of use. For example, blending with a hair dye, a perm solution, and a shaving agent is included, and a composition of about 2 to 10% by weight of zeolite and sericite is blended with respect to the hair dye, the perm solution, or the shaving agent. The For the blending, a pre-blended preparation may be prepared, but it may be used as a combination preparation (kit preparation). After blending into hair dye, perm solution, shaving agent, etc., after hair dyeing, perm, shaving, etc. is completed, it is safe to dye hair without itching, rough skin, soreness, pain, and allergic symptoms.・ Perm and shave.

以下で本発明を実施例と実験例で説明するが、本発明の具体例を例示するものであって、本発明の本質は、ゼオライトとセリサイトの併用が各種疾患に対して相乗効果を発揮することを初めて見出したことであり、この本質であるかぎり、全てが本発明の範囲内にある。   The present invention will be described below with reference to examples and experimental examples. The examples of the present invention are illustrated below, and the essence of the present invention is that the combined use of zeolite and sericite exerts a synergistic effect on various diseases. As long as it is this essence, everything is within the scope of the present invention.

製剤例1−1
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-1
Same-weight mixture of zeolite (Izuka Co., Ltd., Izukalite 63) with a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with an average particle size of 2 μm and water. (10 g of water is added per 5 g of the mixture to obtain a suspension) to obtain a suspension, and 15 g of Japanese paper (1 mm thick, 80 mm long, 100 mm wide) is immersed in the suspension to fully The mixture was soaked. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−2
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-2
75 parts by weight of zeolite (Izuka Co., Ltd., Izucalite 63) with a particle size of 63 μm or less and sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm Part of the mixture and water were mixed (10 g of water was added per 5 g of the mixture to obtain a suspension) to obtain a suspension, and 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) was immersed in the suspension. Let the Japanese paper soak into the mixture. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−3
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)25重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-3
75 parts by weight of zeolite having a particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) and sericite having a maximum particle size of 20 μm and an average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica Z20) 25 parts by weight Mix the mixture and water (add 10 g of water per 5 g of the mixture to obtain a suspension) to obtain a suspension, and immerse 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) in the suspension. Thoroughly soak the mixture into Japanese paper. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−4
粒子径が250μm以下であるゼオライト((株)イズカ製、イズカライト250)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-4
Same-weight mixture of zeolite (Izuka Co., Ltd., Izukalite 250) with a particle size of 250 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with an average particle size of 20 μm and an average particle size of 2 μm and water (10 g of water is added per 5 g of the mixture to obtain a suspension) to obtain a suspension, and 15 g of Japanese paper (1 mm thick, 80 mm long, 100 mm wide) is immersed in the suspension to fully The mixture was soaked. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−5
粒子径が75μm〜250μmであるゼオライト(サンゼオライト工業(株)、サンゼオライトSS)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-5
Same weight of zeolite (Sun Zeolite Industry Co., Ltd., Sun Zeolite SS) with particle size of 75μm to 250μm and sericite with maximum particle size of 20μm and average particle size of 2μm (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) Mix the mixture and water (add 10 g of water per 5 g of mixture to obtain a suspension) to obtain a suspension, and immerse 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) into the suspension. The mixture was soaked in Japanese paper. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−6
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-6
Mixing a mixture of the same weight of zeolite (Izuka Co., Ltd., Izukalite 63) with a particle size of 63 μm or less and sericite (Sanshin Mining Co., Ltd., Sanshin Mika FSE) with an average particle size of 10 μm and water (mixture) Add 10 g of water per 5 g to obtain a suspension) to obtain a suspension, and immerse 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) into the suspension, and thoroughly soak the mixture into the Japanese paper I didn't. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−7
平均粒子径が20μmである高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-7
Mixing the same weight mixture of high-purity zeolite (Table 5) with an average particle size of 20 μm and sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm and water (mixture) Add 10 g of water per 5 g to obtain a suspension) to obtain a suspension, and immerse 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) into the suspension, and thoroughly soak the mixture into the Japanese paper I didn't. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−8
平均粒子径が20μmである高純度ゼオライト(表5)25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-8
A mixture of 25 parts by weight of high-purity zeolite (Table 5) with an average particle size of 20 μm and 75 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm; Mix water (add 10 g of water per 5 g of mixture to obtain a suspension) to obtain a suspension, and immerse 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) into the suspension. Soaked the mixture. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−9
平均粒子径が20μmである高純度ゼオライト(表5)75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)25重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-9
A mixture of 75 parts by weight of high-purity zeolite (Table 5) with an average particle size of 20 μm and 25 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with an average particle size of 20 μm and an average particle size of 2 μm and water (10 g of water is added per 5 g of the mixture to obtain a suspension) to obtain a suspension, and 15 g of Japanese paper (1 mm thick, 80 mm long, 100 mm wide) is immersed in the suspension to fully The mixture was soaked. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−10
平均粒子径が20μmである高純度ゼオライト(表5)40重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)60重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-10
A mixture of 40 parts by weight of high-purity zeolite (Table 5) with an average particle size of 20 μm and 60 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with an average particle size of 20 μm and an average particle size of 2 μm and water (10 g of water is added per 5 g of the mixture to obtain a suspension) to obtain a suspension, and 15 g of Japanese paper (1 mm thick, 80 mm long, 100 mm wide) is immersed in the suspension to fully The mixture was soaked. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−11
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液に和紙(厚さ1mm、縦80mm、横100mm)15gを浸漬させ十分に和紙に混合物を染みこませた。その後、和紙を乾燥させ、外用剤を調製した。なお、コントロールには、混合物の代わりに各単品を同量使い外用剤を調製した。
Formulation Example 1-11
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10μm (water per 5g of the mixture) 10 g was added to obtain a suspension, and a suspension was obtained. 15 g of Japanese paper (thickness 1 mm, length 80 mm, width 100 mm) was immersed in the suspension, and the mixture was sufficiently impregnated into the Japanese paper. Thereafter, the Japanese paper was dried to prepare an external preparation. As a control, an external preparation was prepared using the same amount of each single item instead of the mixture.

製剤例1−12
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液4gと以下のブローネ(登録商標)製品(1剤と2剤)とを用時混合用染毛剤として調製した:
1剤40g 成分:パラアミノフェノール、メタアミノフェノール、トルエン-2,5-ジアミン、レゾルシン、パラアミノオルトクレゾール、精製水、ステアリルアルコール、PG、モノエタノールアミン、ポリオキシエチレンセチルエーテル、塩化ジメチルジアリルアンモニウム・アクリルアミド共重合体液、強アンモニア水、メチルポリシロキサン、流動パラフィン、塩化ジメチルジアリルアンモニウム・アクリル酸共重合体液、ベへニルアルコール、オレイルアルコール、ポリ塩化ジメチルメチレンピペリジニウム液、高重合メチルポリシロキサン(1)塩化ステアリルトリメチルアンモニウム、アミノエチルアミノプロピル・メチルポリシロキサン共重合体、香料、無水亜硫酸ナトリウム、アスコルビン酸、炭酸水素アンモニウム、塩化ジアルキル(12〜18)ジメチルアンモニウム液、エデト酸塩、イソプロパノール、長鎖ン二塩基酸ビス3−メトキシプロピルアミド、カモミラエキス(1)、海藻エキス(1)、ローヤルゼリーエキス、1,3−ブチレングリコール、エタノール、リン酸
2剤40g 成分:過酸化水素水、製氷水、流動パラフィン、ベヘニルアルコール、濃グリセリン、濃グリセリン、ポリオキシエチレンセチルエーテル、ステアリルアルコール、塩化アルキルトリメチルアンモニウム、トリメチルグリシン、エタノール、ヒドロキシエタンジボスホン酸液、硫酸オキシキノリン(2)水酸化ナトリウム液、リン酸
この混合製剤を使用し、染毛処理した結果は、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 1-12
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10μm (water per 5g of the mixture) 10 g was added to obtain a suspension) to obtain a suspension, and 4 g of the suspension and the following Brone (registered trademark) products (one agent and two agents) were prepared as a hair dye for mixing at the time of use. :
1 agent 40g Ingredients: Paraaminophenol, metaaminophenol, toluene-2,5-diamine, resorcin, paraaminoorcresol, purified water, stearyl alcohol, PG, monoethanolamine, polyoxyethylene cetyl ether, dimethyldiallylammonium chloride / acrylamide Copolymer liquid, strong ammonia water, methylpolysiloxane, liquid paraffin, dimethyldiallylammonium chloride / acrylic acid copolymer liquid, behenyl alcohol, oleyl alcohol, polydimethylmethylenepiperidinium chloride liquid, highly polymerized methylpolysiloxane (1 ) Stearyltrimethylammonium chloride, aminoethylaminopropyl / methylpolysiloxane copolymer, fragrance, anhydrous sodium sulfite, ascorbic acid, ammonium bicarbonate, dialkyl chloride 12-18) Dimethylammonium solution, edetate, isopropanol, long-chain dibasic acid bis-3-methoxypropylamide, chamomile extract (1), seaweed extract (1), royal jelly extract, 1,3-butylene glycol, ethanol , Phosphoric acid 2 parts 40g Ingredients: Hydrogen peroxide water, ice making water, liquid paraffin, behenyl alcohol, concentrated glycerin, concentrated glycerin, polyoxyethylene cetyl ether, stearyl alcohol, alkyltrimethylammonium chloride, trimethylglycine, ethanol, hydroxyethane dibos Phosphonic acid solution, oxyquinoline sulfate (2) sodium hydroxide solution, phosphoric acid Using this mixed preparation, the result of hair dyeing treatment was good with no itching or skin eczema.

製剤例1−13
製剤例1−12と、懸濁剤を8g使用する以外は同様にして、用時混合製剤として調製した。この混合製剤を使用し、染毛処理した結果も、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 1-13
It was prepared as a mixed preparation at the time of use in the same manner except that Preparation Example 1-12 and 8 g of the suspension were used. As a result of using this mixed preparation and performing a hair dyeing treatment, neither itching nor skin eczema occurred, and the result was good.

製剤例1−14
平均粒子径が20μmである高純度ゼオライト(表5)30重量部と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の70重量部の混合物と水を混合(混合物5gあたり水を10g添加し、懸濁液をえる)し懸濁液を得、その懸濁液6gと以下のシェロ(登録商標)製品(1剤と2剤)とを用時混合染毛剤として調製した:
1剤60g 成分: 5一アミノオルトクレゾール、パラアミノフェノール、パラフエニレンジアミン、メタアミノフエノール、レゾルシンその他の成分:HEDTA・3Na液、PEG-8、PEG(20)、POEセチルエーテル、アミノエチルァミノプロピルメチル、シロキサン・ジメチルシロキサン共重合体、アラキルァルコール、エデト酸塩、オリブ油、キシリトール、ジエチレントリァミン5酢酸5Na液、水溶性コラーゲン液一3、ステアリルァルコール、セテアリルァルコール、タウリン、月見草油、テアニン、フィトステロール、ブドウ種子油、ベヘニルアルコール、ポリ塩化ジメチルメチレンピペリジニウム液、ミツロウ、無水亜鉛酸Na,モノエタノールアミン、ワセリン、Ph調整剤、黄203
2剤60g 有効成分:過酸化水素水その他の成分:PG、POE(20) POP(4)セチルエーテル、POEセチルエーテル、イソステアリルアルコール、クエン酸、ステアルトリモニウムクロリド、セタノール、フエノキシエタノール
この混合製剤を使用し、染毛処理した結果は、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 1-14
30 parts by weight of high-purity zeolite (Table 5) with an average particle size of 20 μm and 70 parts by weight of sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10 μm are mixed with water ( 10 g of water is added per 5 g of the mixture to obtain a suspension. A suspension is obtained, and 6 g of the suspension and the following Shero (registered trademark) products (one agent and two agents) are mixed at the time of use. Prepared as an agent:
1 agent 60g Ingredients: 5 monoaminoorthocresol, paraaminophenol, paraphenylenediamine, metaaminophenol, resorcin Other components: HEDTA 3Na solution, PEG-8, PEG (20), POE cetyl ether, aminoethylamino Propylmethyl, siloxane / dimethylsiloxane copolymer, araalkyl alcohol, edetate, olive oil, xylitol, diethylenetriamine pentaacetic acid 5Na solution, water-soluble collagen solution 1, stearyl alcohol, cetearyl alcohol, taurine, Evening primrose oil, theanine, phytosterol, grape seed oil, behenyl alcohol, polydimethylmethylenepiperidinium solution, beeswax, anhydrous zinc acid, monoethanolamine, petrolatum, Ph regulator, yellow 203
2 agents 60g Active ingredient: Hydrogen peroxide water Other ingredients: PG, POE (20) POP (4) Cetyl ether, POE cetyl ether, isostearyl alcohol, citric acid, steartrimonium chloride, cetanol, phenoxyethanol The result of the hair dyeing treatment using the mixed preparation was good with no itching or eczema on the skin.

製剤例1−15
製剤例1−14と、懸濁剤を12g使用する以外は同様にして、用時混合製剤として調製した。この混合製剤を使用し、染毛処理した結果も、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 1-15
It was prepared as a mixed preparation at the same time except that Preparation Example 1-14 and 12 g of the suspension were used. As a result of using this mixed preparation and performing a hair dyeing treatment, neither itching nor skin eczema occurred, and the result was good.

製剤例2−1
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-1
Same-weight mixture of zeolite (Izuka Co., Ltd., Izukalite 63) with a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with an average particle size of 2 μm and water. (5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−2
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-2
75 parts by weight of zeolite (Izuka Co., Ltd., Izukalite 63) having a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mika Z20) having a maximum particle size of 20 μm and an average particle size of 2 μm. A mixture of parts by weight and water were mixed (5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded formulation.

製剤例2−3
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-3
25 parts by weight of zeolite (Izuka Co., Ltd., Izucalite 63) with a particle size of 63 μm or less and sericite with a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Industries Co., Ltd., Yodogawa Mica Z20) A mixture of parts by weight and water were mixed (5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded formulation.

製剤例2−4
粒子径が75μm〜250μmであるゼオライト(サンゼオライト工業(株)、サンゼオライトSS)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-4
A mixture of the same weight of zeolite (San Zeolite Industry Co., Ltd., Sun Zeolite SS) with a particle size of 75 μm to 250 μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mika FSE) with an average particle size of 10 μm and water. Mixing (adding 5 g of water per 5 g of the mixture to obtain a kneaded product) gave a kneaded preparation.

製剤例2−5
平均粒子径が20μmである高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-5
Mixing the same weight mixture of high-purity zeolite (Table 5) with an average particle size of 20 μm and sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm and water (mixture) 5 g of water was added per 5 g to obtain a kneaded product, and a kneaded preparation was obtained.

製剤例2−6
平均粒子径が20μmである高純度ゼオライト(表5)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-6
A mixture of 25 parts by weight of high-purity zeolite having an average particle size of 20 μm (Table 5) and 75 parts by weight of sericite having a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20). And water were mixed (5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−7
平均粒子径が20μmである高純度ゼオライト(表5)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-7
A mixture of 75 parts by weight of high-purity zeolite (Table 5) with an average particle diameter of 20 μm and 25 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle diameter of 20 μm and an average particle diameter of 2 μm. And water were mixed (5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−8
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-8
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10μm (water per 5g of the mixture) 5 g was added to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−9
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を1.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-9
Same-weight mixture of zeolite (Izuka Co., Ltd., Izukalite 63) with a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with an average particle size of 2 μm and water. Were mixed (1.5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−10
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を2.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-10
75 parts by weight of zeolite (Izuka Co., Ltd., Izukalite 63) having a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mika Z20) having a maximum particle size of 20 μm and an average particle size of 2 μm. A mixture of parts by weight and water were mixed (2.5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded formulation.

製剤例2−11
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を1.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-11
25 parts by weight of zeolite (Izuka Co., Ltd., Izucalite 63) with a particle size of 63 μm or less and sericite with a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Industries Co., Ltd., Yodogawa Mica Z20) A mixture of a part by weight and water were mixed (1.5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded formulation.

製剤例2−12
粒子径が75μm〜250μmであるゼオライト(サンゼオライト工業(株)、サンゼオライトSS)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を2g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-12
A mixture of the same weight of zeolite (San Zeolite Industry Co., Ltd., Sun Zeolite SS) with a particle size of 75 μm to 250 μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mika FSE) with an average particle size of 10 μm and water. Mixing (adding 2 g of water per 5 g of the mixture to obtain a kneaded product) gave a kneaded preparation.

製剤例2−13
平均粒子径が20μmである高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を2g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-13
Mixing the same weight mixture of high-purity zeolite (Table 5) with an average particle size of 20 μm and sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm and water (mixture) 2 g of water was added per 5 g to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−14
平均粒子径が20μmである高純度ゼオライト(表5)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を3g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-14
A mixture of 25 parts by weight of high-purity zeolite having an average particle size of 20 μm (Table 5) and 75 parts by weight of sericite having a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20). And water were mixed (3 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−15
平均粒子径が20μmである高純度ゼオライト(表5)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を2.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-15
A mixture of 75 parts by weight of high-purity zeolite (Table 5) with an average particle diameter of 20 μm and 25 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle diameter of 20 μm and an average particle diameter of 2 μm. And water were mixed (2.5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−16
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を2.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-16
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10μm (water per 5g of the mixture) 2.5 g was added to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−17
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を3g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-17
Same-weight mixture of zeolite (Izuka Co., Ltd., Izukalite 63) with a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with an average particle size of 2 μm and water. (3 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−18
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を3.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-18
75 parts by weight of zeolite (Izuka Co., Ltd., Izukalite 63) having a particle size of 63 μm or less and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mika Z20) having a maximum particle size of 20 μm and an average particle size of 2 μm. A mixture of parts by weight and water were mixed (3.5 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−19
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を3g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-19
25 parts by weight of zeolite (Izuka Co., Ltd., Izucalite 63) with a particle size of 63 μm or less and sericite with a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Industries Co., Ltd., Yodogawa Mica Z20) A mixture of a part by weight and water were mixed (3 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded formulation.

製剤例2−20
粒子径が75μm〜250μmであるゼオライト(サンゼオライト工業(株)、サンゼオライトSS)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を3.5g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-20
A mixture of the same weight of zeolite (San Zeolite Industry Co., Ltd., Sun Zeolite SS) with a particle size of 75 μm to 250 μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mika FSE) with an average particle size of 10 μm and water. Mixing (adding 3.5 g of water per 5 g of the mixture to obtain a kneaded product) gave a kneaded preparation.

製剤例2−21
平均粒子径が20μmである高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物5gあたり水を3g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-21
Mixing the same weight mixture of high-purity zeolite (Table 5) with an average particle size of 20 μm and sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20 μm and an average particle size of 2 μm and water (mixture) 3 g of water was added per 5 g to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−22
平均粒子径が20μmである高純度ゼオライト(表5)の25重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の75重量部の混合物と水を混合(混合物5gあたり水を3.1g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-22
A mixture of 25 parts by weight of high-purity zeolite having an average particle size of 20 μm (Table 5) and 75 parts by weight of sericite having a maximum particle size of 20 μm and an average particle size of 2 μm (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20). And water were mixed (3.1 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−23
平均粒子径が20μmである高純度ゼオライト(表5)の75重量部と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の25重量部の混合物と水を混合(混合物5gあたり水を3.3g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-23
A mixture of 75 parts by weight of high-purity zeolite (Table 5) with an average particle diameter of 20 μm and 25 parts by weight of sericite (Yodogawa Mika Co., Ltd., Yodogawa Mica Z20) with a maximum particle diameter of 20 μm and an average particle diameter of 2 μm. And water were mixed (3.3 g of water was added per 5 g of the mixture to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−24
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物5gあたり水を3.4g添加し、練状物をえる)し練状製剤を得た。
Formulation Example 2-24
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10μm (water per 5g of the mixture) 3.4 g was added to obtain a kneaded product) to obtain a kneaded preparation.

製剤例2−25
平均粒子径が20μmである高純度ゼオライト(表5)30重量部と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の70重量部の混合物と水を混合(混合物10gあたり水を7g添加し、練り状物をえる)し練り状物を得、その練り状物4gと以下のブローネ(登録商標)製品(1剤と2剤)とを用時混合染毛剤として調製した:
1剤40g 成分:パラアミノフェノール、メタアミノフェノール、トルエン-2,5-ジアミン、レゾルシン、パラアミノオルトクレゾール、精製水、ステアリルアルコール、PG、モノエタノールアミン、ポリオキシエチレンセチルエーテル、塩化ジメチルジアリルアンモニウム・アクリルアミド共重合体液、強アンモニア水、メチルポリシロキサン、流動パラフィン、塩化ジメチルジアリルアンモニウム・アクリル酸共重合体液、ベへニルアルコール、オレイルアルコール、ポリ塩化ジメチルメチレンピペリジニウム液、高重合メチルポリシロキサン(1)塩化ステアリルトリメチルアンモニウム、アミノエチルアミノプロピル・メチルポリシロキサン共重合体、香料、無水亜硫酸ナトリウム、アスコルビン酸、炭酸水素アンモニウム、塩化ジアルキル(12〜18)ジメチルアンモニウム液、エデト酸塩、イソプロパノール、長鎖ン二塩基酸ビス3−メトキシプロピルアミド、カモミラエキス(1)、海藻エキス(1)、ローヤルゼリーエキス、1,3−ブチレングリコール、エタノール、リン酸
2剤40g 成分:過酸化水素水、製氷水、流動パラフィン、ベヘニルアルコール、濃グリセリン、濃グリセリン、ポリオキシエチレンセチルエーテル、ステアリルアルコール、塩化アルキルトリメチルアンモニウム、トリメチルグリシン、エタノール、ヒドロキシエタンジボスホン酸液、硫酸オキシキノリン(2)水酸化ナトリウム液、リン酸
この混合製剤を使用し、通常の方法により染毛処理した結果は、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 2-25
30 parts by weight of high-purity zeolite (Table 5) with an average particle size of 20 μm and 70 parts by weight of sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10 μm are mixed with water ( 7 g of water is added per 10 g of the mixture to obtain a kneaded product) to obtain a kneaded product, and 4 g of the kneaded product and the following Brone (registered trademark) products (one agent and two agents) are mixed at the time of use Prepared as an agent:
1 agent 40g Ingredients: Paraaminophenol, metaaminophenol, toluene-2,5-diamine, resorcin, paraaminoorcresol, purified water, stearyl alcohol, PG, monoethanolamine, polyoxyethylene cetyl ether, dimethyldiallylammonium chloride / acrylamide Copolymer liquid, strong ammonia water, methylpolysiloxane, liquid paraffin, dimethyldiallylammonium chloride / acrylic acid copolymer liquid, behenyl alcohol, oleyl alcohol, polydimethylmethylenepiperidinium chloride liquid, highly polymerized methylpolysiloxane (1 ) Stearyltrimethylammonium chloride, aminoethylaminopropyl / methylpolysiloxane copolymer, fragrance, anhydrous sodium sulfite, ascorbic acid, ammonium bicarbonate, dialkyl chloride 12-18) Dimethylammonium solution, edetate, isopropanol, long-chain dibasic acid bis-3-methoxypropylamide, chamomile extract (1), seaweed extract (1), royal jelly extract, 1,3-butylene glycol, ethanol , Phosphoric acid 2 parts 40g Ingredients: Hydrogen peroxide water, ice making water, liquid paraffin, behenyl alcohol, concentrated glycerin, concentrated glycerin, polyoxyethylene cetyl ether, stearyl alcohol, alkyltrimethylammonium chloride, trimethylglycine, ethanol, hydroxyethane dibos Phosphonic acid solution, oxyquinoline sulfate (2) sodium hydroxide solution, phosphoric acid Using this mixed preparation, the result of hair dyeing treatment by a usual method was good with no itching or skin eczema.

製剤例2−26
製剤例2−25と、練り状物を8g使用する以外は同様とし、用時混合製剤として調製した。この混合製剤を使用し、通常の方法により染毛処理した結果も、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 2-26
Formulation Example 2-25 was prepared in the same manner except that 8 g of the kneaded product was used, and prepared as a mixed preparation at the time of use. Using this mixed preparation, the result of hair dyeing treatment by a usual method was also good with no itching or eczema on the skin.

製剤例2−27
平均粒子径が20μmである高純度ゼオライト(表5)と平均粒子径が10μmであるセリサイト(三信鉱工(株)、三信マイカFSE)の同重量混合物と水を混合(混合物10gあたり水を7g添加し、練り状物をえる)し練り状物を得、その練り状物6gと以下のシェロ(登録商標)製品(1剤と2剤)と用時混合染毛剤として調製した:
1剤60g 有効成分: 5一アミノオルトクレゾール、パラアミノフェノール、パラフエニレンジアミン、メタアミノフエノール、レゾルシンその他の成分:HEDTA・3Na液、PEG-8、PEG(20)、POEセチルエーテル、アミノエチルァミノプロピルメチル、シロキサン・ジメチルシロキサン共重合体、アラキルァルコール、エデト酸塩、オリブ油、キシリトール、ジエチレントリァミン5酢酸5Na液、水溶性コラーゲン液一3、ステアリルァルコール、セテアリルァルコール、タウリン、月見草油、テアニン、フィトステロール、ブドウ種子油、ベヘニルアルコール、ポリ塩化ジメチルメチレンピペリジニウム液、ミツロウ、無水亜鉛酸Na,モノエタノールアミン、ワセリン、Ph調整剤、黄203
2剤60g 有効成分:過酸化水素水その他の成分:PG、POE(20) POP(4)セチルエーテル、POEセチルエーテル、イソステアリルアルコール、クエン酸、ステアルトリモニウムクロリド、セタノール、フエノキシエタノール
この混合製剤を使用し、通常の方法により染毛処理した結果は、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 2-27
Mix the same-weight mixture of high-purity zeolite (Table 5) with an average particle size of 20 μm and sericite (Sanshin Mining Co., Ltd., Sanshin Mica FSE) with an average particle size of 10 μm (water per 10 g of the mixture) 7 g was added to obtain a kneaded product, and a kneaded product was obtained, and 6 g of the kneaded product and the following Cello (registered trademark) products (one agent and two agents) were prepared as a mixed hair dye at the time of use:
1 agent 60g Active ingredient: 5 mono-aminoorthocresol, paraaminophenol, paraphenylenediamine, metaaminophenol, resorcin Other ingredients: HEDTA 3Na solution, PEG-8, PEG (20), POE cetyl ether, aminoethyla Minopropylmethyl, siloxane-dimethylsiloxane copolymer, araalkyl alcohol, edetate, olive oil, xylitol, diethylenetriamine pentaacetic acid 5Na solution, aqueous collagen solution 1, stearyl alcohol, cetearyl alcohol, taurine , Evening primrose oil, theanine, phytosterol, grape seed oil, behenyl alcohol, polydimethylmethylenepiperidinium solution, beeswax, sodium zinc anhydride, monoethanolamine, petrolatum, Ph adjuster, yellow 203
2 agents 60g Active ingredient: Hydrogen peroxide water Other ingredients: PG, POE (20) POP (4) Cetyl ether, POE cetyl ether, isostearyl alcohol, citric acid, steartrimonium chloride, cetanol, phenoxyethanol The results of using a mixed preparation and dyeing the hair by the usual method were good with no itching or eczema on the skin.

製剤例2−28
製剤例2−27と、懸濁剤を12g使用する以外は同様とし、用時混合製剤として調製した。この混合製剤を使用し、通常の方法により染毛処理した結果も、痒みも肌の湿疹もおこらず良好であった。
Formulation Example 2-28
Formulation Example 2-27 was prepared in the same manner as in Example 12 except that 12 g of the suspension was used. Using this mixed preparation, the result of hair dyeing treatment by a usual method was also good with no itching or eczema on the skin.

製剤例3
製剤例2−1〜2−24で得た練状物を、80mm×100mmの不織布に0.5mmの厚さに塗布し、乾燥を防ぐために、セロハンを上から重ねて、各外用剤を調製した。
Formulation Example 3
Each kneaded product obtained in Formulation Examples 2-1 to 2-24 was applied to a non-woven fabric of 80 mm × 100 mm to a thickness of 0.5 mm, and cellophane was stacked from above to prepare each external preparation to prevent drying. did.

製剤例4
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物を十分に攪拌し、粉末製剤を調製した。また、ゼオライト:セリサイト=25:75重量混合物、75:25重量混合物を得て、各粉末製剤を調製した。
Formulation Example 4
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) The same weight mixture of Z20) was sufficiently stirred to prepare a powder formulation. Moreover, zeolite: sericite = 25: 75 weight mixture and 75:25 weight mixture were obtained, and each powder formulation was prepared.

製剤例5
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物20gあたり水を30g添加し、懸濁液をえる)し懸濁液を得た。懸濁液を紙の製造工程中で混合し、その後、紙を乾燥、調製させ、トイレットペーパーを調製した。同様に、ティッシュ、紙生理用品、紙おむつを調製した。また、ゼオライト:セリサイト=25:75重量混合物、75:25重量混合物を同様に使い各製品を調製した。
Formulation Example 5
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A mixture of the same weight of Z20) and water were mixed (30 g of water was added per 20 g of the mixture to obtain a suspension) to obtain a suspension. The suspension was mixed during the paper manufacturing process, after which the paper was dried and prepared to prepare toilet paper. Similarly, tissues, paper sanitary products, and paper diapers were prepared. Each product was prepared in the same manner using zeolite: sericite = 25: 75 weight mixture and 75:25 weight mixture.

製剤例6
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物20gあたり水を30g添加し、懸濁液をえる)し懸濁液を得、布製製品(生理用品、脱脂綿、ガーゼ、不織布、オムツ)の1cm平方当り 0.5ccの懸濁液を噴霧し、調製した。また、ゼオライト:セリサイト=25:75重量混合物、75:25重量混合物を同様に使い各製品を調製した。
Formulation Example 6
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) Mix the same weight mixture of Z20) and water (add 30 g of water per 20 g of mixture to obtain a suspension) to obtain a suspension, and 1 cm square of fabric product (sanitary products, absorbent cotton, gauze, non-woven fabric, diaper) A 0.5 cc suspension per spray was prepared by spraying. Each product was prepared in the same manner using zeolite: sericite = 25: 75 weight mixture and 75:25 weight mixture.

製剤例7
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物50mgを、3号カプセルに充填し、カプセル製剤をえた。また、ゼオライト:セリサイト=25:75重量混合物、75:25重量混合物を同様に使い各カプセル製剤を調製した。
Formulation Example 7
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A No. 3 capsule was filled with 50 mg of the same weight mixture of Z20) to obtain a capsule preparation. Further, each capsule preparation was prepared using zeolite: sericite = 25: 75 weight mixture and 75:25 weight mixture in the same manner.

製剤例8
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物50mgあたり水を100g添加し、混合液をえる)し混合液を得、経口摂取用水溶液製剤を調製した。また、ゼオライト:セリサイト=25:75重量混合物、75:25重量混合物を同様に使い各経口摂取用水溶液製剤を調製した。
Formulation Example 8
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A mixture of the same weight of Z20) and water were mixed (100 g of water was added per 50 mg of mixture to obtain a mixed solution) to obtain a mixed solution to prepare an aqueous solution preparation for oral consumption. In addition, zeolite: sericite = 25: 75 weight mixture and 75:25 weight mixture were used in the same manner to prepare aqueous solutions for oral intake.

製剤例9
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物とふりかけ成分を混合(混合物50mgあたりふりかけ成分を50g)添加し、混合物をえる)し混合物を得、経口摂取用製剤を調製した。
Formulation Example 9
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A mixture of Z20) having the same weight and the sprinkling component were mixed (50 g of sprinkling component was added per 50 mg of the mixture to obtain a mixture) to obtain a mixture, and a preparation for oral consumption was prepared.

製剤例10
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と寒天粉を混合(混合物50mgあたり寒天粉末を50g添加し、混合物をえる)し混合物を得、水に溶かしたのち、ゼリー化し、経口摂取用製剤を調製した。
Formulation Example 10
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A mixture of the same weight of Z20) and agar powder were mixed (50 g of agar powder was added per 50 mg of mixture to obtain a mixture) to obtain a mixture, which was dissolved in water and then jellied to prepare a preparation for oral consumption.

製剤例11
粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と石鹸成分を混合(混合物10gあたり石鹸成分を50g添加し、混合物をえる)し混合物を得、固形化し、石鹸製剤を調製した。シャンプーの場合は、シャンプー液中に3重量%配合調製した。入浴剤の場合は、混合物と入浴剤成分を80:20で混合し調製した。エステ用製剤は、製剤例2の練状製剤を使用できる。
Formulation Example 11
Zeolite with particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high purity zeolite (Table 5) and sericite with maximum particle size of 20 μm and average particle size of 2 μm (manufactured by Yodogawa Industries Co., Ltd., Yodogawa Mica) A mixture of the same weight of Z20) and a soap component was mixed (50 g of soap component was added per 10 g of the mixture to obtain a mixture) to obtain a mixture, which was solidified to prepare a soap formulation. In the case of shampoo, 3% by weight was prepared in the shampoo solution. In the case of a bath agent, the mixture and the bath component were mixed at 80:20. As the esthetic preparation, the kneaded preparation of Preparation Example 2 can be used.

製剤例12
犬猫用フードの調製には、粒子径が63μm以下であるゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と犬猫用フード成分を混合(混合物5mgあたり犬猫用フード成分を200mg添加し、混合物をえる)し混合物を得、これに水を混合(混合物205mgあたり水を205mg添加し、練状物をえる)し練状物半乾燥化させ、犬猫用半乾燥製剤をえた。
Formulation Example 12
For the preparation of food for dogs and cats, zeolite with a particle size of 63 μm or less (Izuka Co., Ltd., Izukalite 63) or high-purity zeolite (Table 5) and sericite with a maximum particle size of 20 μm and an average particle size of 2 μm ( Mix the same weight mixture of Yodogawa Sakai Co., Ltd., Yodogawa Mica Z20) and dog and cat food ingredients (add 200 mg of dog and cat food ingredients per 5 mg of mixture to obtain a mixture) to obtain a mixture, and add water to this Mixing (adding 205 mg of water per 205 mg of mixture to obtain a kneaded product) was semi-dried to obtain a semi-dried product for dogs and cats.

実験例
試験方法
試験方法A:
ゼオライト単体、セリサイト単体、セリサイトとゼオライトを同重量混合したものを、それぞれ水に溶かし其の中に和紙を浸漬させ、それぞれを乾燥させ、それを患部に当てて実験をした。又は、セリサイトとゼオライトの混合品を適当量の水と混合し、ペースト状にして患部に塗って実験をした。厚みは肌が見えるか見えないか程度で良い。コントロールは、ゼオライト単独、または、セリサイト単独を用いて同様に試験した。被験者は、承諾を得たボランテイアである。
試験方法B:
ゼオライト0.5gとセリサイト0.5gを混合し3号カプセル2個に充填し1日に1回、2カプセルを経口にて摂取させた。コントロールは、0.5gのセリライト含有する3号カプセルを1日に1回2カプセル経口摂取、および0.5gのゼオライトを含有する3号カプセルを1日に1回2カプセル経口摂取とした。ゼオライトは、イズカライト63((株)イズカ製)又は高純度ゼオライト(表5)を用いたが、その効果は実質的に略同一であった。なお、高純度ゼオライトは、不純物が少なく、生体内、生体外において使うにあたり、より好ましいものである。セリサイトは、斐川マイカZ20(斐川礦業(株)製)を使った。被験者は、承諾を得たボランテイアである。
結果:
結果を、表1および表2に示した。併用、ゼオライト単独、セリサイト単独での結果を順次示した。表中症状の項は、被験者の処置前の状態を概略的に示し、症状の程度とは各症状の処置前の重篤度を意味し、概略的に低、中、重に分けた。処置後の改善効果の欄の◎は処置開始から改善に向かい完治、○はスピードは緩やかだが改善に向かう(ほとんど治るがほんの少し症状や痛みが残る)、×は少し改善はみられるが治らない場合を示した。数字は処置開始から完治までの日数を意味する。試験法の欄のAおよびBは上記試験方法Aおよび試験方法Bを意味する。
Experimental Example Test Method Test Method A:
Zeolite simple substance, sericite simple substance, and a mixture of the same weight of sericite and zeolite were each dissolved in water, soaked in Japanese paper, dried, and applied to the affected area. Alternatively, a mixture of sericite and zeolite was mixed with an appropriate amount of water, made into a paste, and applied to the affected area. The thickness may be about whether the skin is visible or not visible. Controls were similarly tested using zeolite alone or sericite alone. The test subject is an approved volunteer.
Test method B:
0.5 g of zeolite and 0.5 g of sericite were mixed and filled into 2 capsules of No. 3, and 2 capsules were taken orally once a day. As a control, 3 capsules containing 0.5 g of sericite were orally ingested 2 capsules once a day, and 3 capsules containing 0.5 g of zeolite were orally ingested 2 capsules once a day. The zeolite used was Izukalite 63 (manufactured by Izuka Co., Ltd.) or high-purity zeolite (Table 5), but the effect was substantially the same. High-purity zeolite has less impurities and is more preferable for use in vivo and in vitro. As the sericite, Yodogawa Mica Z20 (manufactured by Yodogawa Industries) was used. The test subject is an approved volunteer.
result:
The results are shown in Tables 1 and 2. The results of combined use, zeolite alone, and sericite alone are shown in order. The symptom section in the table schematically shows the state of the subject before treatment, and the degree of symptom means the severity before treatment of each symptom, and is roughly divided into low, medium and heavy. ◎ in the column of improvement effect after treatment is completely cured from the start of treatment, ○ is slow but it is gradually improved (almost cured but a little symptom or pain remains), x is slightly improved but not cured Showed the case. The numbers mean the number of days from the start of treatment to complete cure. A and B in the column of the test method mean the above test method A and test method B.

試験例1〜3は、陰部の痒み、ただれ、痛みのある女性ボランテイアであり、製剤例2−1の練状製剤を患部に3箇所に分けて塗りこんだ。ゼオライト((株)イズカ製、イズカライト63)又は高純度ゼオライト(表5)の効果は実質的に略同一であった。その結果、混合製剤部分は、3日で完治したのに対し、ゼオライト単独製剤部分は10日でやや改善、セリサイト単独製剤部分は5日でほぼ改善という効果であった。試験例4〜6は、同様に、陰部の痒み、ただれ、痛みのある女性ボランテイアであり、製剤例2−1の練状製剤を患部に3箇所に分けて塗りこんだ。その結果、混合製剤部分は、4日で完治したのに対し、ゼオライト単独製剤部分は9日でやや改善、セリサイト単独製剤部分は6日でほぼ改善という効果であった。試験例7〜9は、陰部股のただれ、痒みのある男性ボランテイアで製剤例2−1の練状製剤を患部に3箇所に分けて塗りこんだ。その結果、混合製剤部分は、5日で完治したのに対し、ゼオライト単独製剤部分は14日でやや改善、セリサイト単独製剤部分は8日でほぼ改善という効果であった。   Test Examples 1 to 3 are female volunteers with itching, soreness, and pain in the genital area. The kneaded preparation of Preparation Example 2-1 was applied to the affected area in three places. The effects of zeolite (manufactured by Izuka Co., Ltd., Izukalite 63) or high-purity zeolite (Table 5) were substantially the same. As a result, the mixed preparation part was completely cured in 3 days, while the zeolite single preparation part was slightly improved in 10 days, and the sericite single preparation part was substantially improved in 5 days. Similarly, Test Examples 4 to 6 are female volunteers with itching, soreness, and pain in the genital area. The kneaded preparation of Preparation Example 2-1 was applied to the affected part in three places. As a result, the mixed preparation part was completely cured in 4 days, while the zeolite single preparation part was slightly improved in 9 days, and the sericite single preparation part was substantially improved in 6 days. In Test Examples 7 to 9, the kneaded preparation of Preparation Example 2-1 was applied to the affected area in three places with a male volunteer with a pubic crotch and itching. As a result, the mixed preparation portion was completely cured in 5 days, whereas the zeolite single preparation portion was slightly improved in 14 days, and the sericite single preparation portion was almost improved in 8 days.

試験例10は、0歳〜15歳のアトピー性皮膚炎と診断された男性ボランテイアで、炎症部位に製剤例2−1の練状製剤を塗りこんだ。その結果、混合製剤は、3〜5日で完治したのに対し、ゼオライト単独製剤は無効、セリサイト単独製剤は無効という効果であった。
試験例11、12、13もアトピー性皮膚炎と診断されたボランテイアに試験例10と同様に塗布したところ、同等の結果であった。
試験例14〜16は、アトピー性皮膚炎と診断された男性ボランテイアで、製剤例2−1の練状製剤を患部に3箇所に分けて塗りこんだ。その結果、混合製剤部分は、7日で完治したのに対し、ゼオライト単独製剤部分は無効、セリサイト単独製剤部分は無効という効果であった。
Test Example 10 was a male volunteer diagnosed with atopic dermatitis aged 0 to 15 years. The kneaded preparation of Preparation Example 2-1 was applied to the inflamed site. As a result, the mixed preparation was completely cured in 3 to 5 days, whereas the zeolite single preparation was ineffective and the sericite single preparation was ineffective.
Test Examples 11, 12, and 13 were also applied to volunteers diagnosed with atopic dermatitis in the same manner as Test Example 10, and the results were equivalent.
Test Examples 14 to 16 were male volunteers diagnosed with atopic dermatitis and applied the kneaded preparation of Preparation Example 2-1 to the affected area in three places. As a result, the mixed preparation part was completely cured in 7 days, whereas the zeolite single preparation part was ineffective and the sericite single preparation part was ineffective.

試験例17〜19は、気管支炎のボランテイア女性で、製剤例2−1の練状製剤を咽喉部、胸部に塗りこんだ。その結果、混合製剤は、1日で完治したのに対し、ゼオライト単独製剤は混合製剤塗り込み15日前から10日間処置したがやや改善程度、セリサイト単独製剤は、混合製剤塗り込み5日前から5日間処置したがやや改善程度という効果であった。
試験例20〜22は、喘息のボランテイア男性で、製剤例2−1の練状製剤を咽喉部、胸部に塗りこんだ。その結果、混合製剤は、1日で完治したのに対し、ゼオライト単独製剤は混合製剤塗り込み24日前から14日間処置したがやや改善程度、セリサイト単独製剤は混合製剤塗り込み10日前から10日間処置したがやや改善程度という効果であった。
Test Examples 17 to 19 are volunteer women with bronchitis, and the paste preparation of Preparation Example 2-1 was applied to the throat and chest. As a result, the mixed preparation was completely cured in one day, while the zeolite single preparation was treated for 10 days from 15 days before the mixed preparation was applied. Although it was treated for a day, the effect was slightly improved.
Test Examples 20 to 22 are asthmatic volunteers who applied the kneaded preparation of Preparation Example 2-1 to the throat and chest. As a result, the mixed preparation was completely cured in one day, whereas the zeolite single preparation was treated for 14 days from 24 days before the mixed preparation was applied. Although it was treated, the effect was a little improved.

試験例23と24は、肉離れと診断されたボランテイアで、肉離れ部位に製剤例2−1の練状製剤を塗りこんだ。その結果、混合製剤は、平均60分で完治したのに対し、ゼオライト単独製剤は2日でやや改善、セリサイト単独製剤は1〜2日でほぼ改善という効果であった。   Test Examples 23 and 24 were volunteers diagnosed with meat separation, and the kneaded preparation of Formulation Example 2-1 was applied to the meat separation site. As a result, the mixed preparations were completely cured in an average of 60 minutes, whereas the zeolite single preparation was slightly improved in 2 days, and the sericite single preparation was almost improved in 1 to 2 days.

皮膚の症状は水分(湿度)と温度が菌の繁殖に適していると症状がひどくなる。痒みがあると掻く、掻くと、傷口に菌がさらに繁殖をする。免疫力より菌の繁殖が強いと症状は改善されない。ゼオライトは有害化学物質、重金属を吸着する、水分を吸湿し湿度の調整機能があり、菌の繁殖を抑え、pHの調節機能があり、ウイルスの吸着効果があり、遠赤効果がある。セリサイトは、皮膚を保護する機能があり、皮膚の適度な保湿効果があり、遠赤効果がある。各単独でも効果があるが、ゼオライト単体では完全に治せない。しかし患部の水分が多い状態の時はゼオライトの効果は大きい。ゼオライト単体と比較するとセリサイト単体の方が効果は大きいが、ゼオライトとセリサイトのブレンドの相乗効果が大きく、格別に高い症状改善効果を発揮し、症状の完治が見られる。
製剤は、厚くすると乾燥して粉がこぼれ落ちるので実用性が小さい。製剤例2−1以外にゼオライトとセリサイトの配合比を10:90〜50:50の範囲で、10:90、25:75についても外用剤としての効果を検討したが略同一傾向であり、セリサイトが必須の主成分となることを確認した。
Skin symptoms become severe when moisture (humidity) and temperature are suitable for bacterial growth. If itching is scratched, the bacteria will propagate further in the wound. Symptoms are not improved if the bacteria grow more strongly than immunity. Zeolite adsorbs toxic chemicals and heavy metals, absorbs moisture and adjusts humidity, suppresses the growth of bacteria, adjusts pH, has the effect of adsorbing viruses, and has a far-red effect. Sericite has a function of protecting the skin, has an appropriate moisturizing effect on the skin, and has a far-red effect. Each single is effective, but zeolite alone cannot be cured completely. However, when the affected area has a lot of moisture, the effect of zeolite is great. Compared to zeolite alone, sericite alone is more effective, but the synergistic effect of the blend of zeolite and sericite is great, and it exhibits a particularly high symptom-improving effect.
The formulation is less practical because it thickens and dries out powder. In addition to formulation example 2-1, the blending ratio of zeolite and sericite was in the range of 10:90 to 50:50, and 10:90 and 25:75 were examined for the effect as an external preparation, but the tendency was almost the same. It was confirmed that sericite is an essential component.

なお、肉離れに本発明組成物の格別の効果も確認された。肉離れへの対処は、スポーツ障害への対処の基本である「RICE」が肉離れ治療の基本であると言われている。RICEとは安静(Rest)・冷却(Ice)・圧迫(Compression)・挙上(Elevation)の頭文字をとった言葉で、「横になって安静」「患部の冷却」「患部の圧迫」「患部を心臓より上に挙げる」という応急処置の鉄則を表している。肉離れが発生してから48時間はRICEに従った治療を継続し、痛みが引いてきたら温熱療法などで回復を促していく。場合によっては抗炎症剤を使って痛みを抑えたり、電気治療、超音治療をしたりと言った治療法が行なわれる。しかしいずれにしても、熱や痛みが無くなるまでにかなり時間、かなりの日数がかかり、元の状態に戻るのには数週間から、数ヶ月かかる。また同じ部分の再発も多い。ここで本発明のゼオライト・セリサイトの混合物からなる組成物を患部に塗ると、痛みや熱は程度によるが、数分から数十分で治まり、処置を繰り返せば、完全治癒までの時間、日数が大幅に短縮される。アスリートにとっては、動けない時間の長さは筋力の衰えの時間でもあり、短い時間での完治は大きなメリットとなる。一般においても、全身における肉離れ等の怪我は多く、老人では、背中の筋肉を痛め肺炎を引起す例もある。RICEの処置で無く、本発明による組成物による処置で、簡単に治療ができ早く治癒する。このような効果を発揮する手段は他に無い。   In addition, the special effect of the composition of the present invention was confirmed for meat separation. In dealing with meat loss, it is said that "RICE", which is the basis for dealing with sports disorders, is the basis for treatment of meat loss. RICE is an acronym for Rest, Cooling, Compression, and Elevation. “Lie down, rest,” “Cooling the affected area,” “Pressing the affected area,” “ This is a first-aid rule that raises the affected area above the heart. Continue to follow RICE treatment for 48 hours after a flesh is released, and if the pain has subsided, use heat therapy to promote recovery. In some cases, anti-inflammatory drugs are used to reduce pain, treat the patient with electrical therapy, or ultrasonic therapy. In any case, however, it takes a considerable amount of time and days to eliminate the fever and pain, and it takes weeks to months to return to the original state. There are also many recurrences of the same part. Here, when the composition comprising the mixture of zeolite and sericite of the present invention is applied to the affected area, the pain and fever depend on the degree, but it can be cured in several minutes to several tens of minutes. Significantly shortened. For athletes, the length of time they can't move is also the time for muscle weakness, and complete cure in a short time is a great merit. In general, there are many injuries such as flesh in the whole body, and in elderly people, there are cases in which the muscles of the back are damaged and pneumonia is caused. The treatment with the composition according to the present invention, not the treatment of RICE, can be easily treated and healed quickly. There is no other means to exert such an effect.

試験例25〜27は、胃潰瘍と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、10日で完治したのに対し、ゼオライト単独製剤は混合製剤処置60日前から30日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置30日前から30日間処置したがやや改善程度という効果であった。試験例28〜30は、十二指腸潰瘍と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、8日で完治したのに対し、ゼオライト単独製剤は混合製剤処置60日前から30日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置30日前から30日間処置したがやや改善程度という効果であった。試験例31〜33は、逆流性胃炎と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、7日で完治したのに対し、ゼオライト単独製剤は混合製剤処置65日前から35日間処置したが無効、セリサイト単独製剤は混合製剤処置30日前から30日間処置したがやや改善程度という効果であった。   Test Examples 25 to 27 are volunteers diagnosed with gastric ulcer, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 10 days, whereas the zeolite single preparation was treated for 30 days from 60 days before the mixed preparation treatment, but the degree of improvement was slightly improved, and the sericite single preparation was treated for 30 days from 30 days before the mixed preparation treatment. However, there was a slight improvement. Test Examples 28 to 30 were volunteers diagnosed with duodenal ulcer, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 8 days, whereas the zeolite single preparation was treated for 30 days from 60 days before the mixed preparation treatment, but the degree of improvement was slightly, and the sericite single preparation was treated for 30 days from 30 days before the mixed preparation treatment. However, there was a slight improvement. Test Examples 31 to 33 are volunteers diagnosed with reflux gastritis, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 7 days, while the zeolite single preparation was treated for 35 days from 65 days before the mixed preparation treatment, but the sericite single preparation was treated for 30 days from 30 days before the mixed preparation treatment. It was the effect of improvement.

試験例35〜37は、口内炎と診断されたボランテイアであり、製剤例2−1の練状製剤を口内炎症部に塗りこんだ。その結果、混合製剤部分は、1日で完治したのに対し、ゼオライト単独製剤は混合製剤処置7日前から4日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置3日前から3日間処置したがやや改善程度という効果であった。   Test Examples 35 to 37 are volunteers diagnosed with stomatitis, and the paste preparation of Preparation Example 2-1 was applied to the inflamed area of the mouth. As a result, while the mixed preparation part was completely cured in one day, the zeolite single preparation was treated for 4 days from 7 days before the mixed preparation treatment, but the degree of improvement was slightly improved, and the sericite single preparation was treated for 3 days from 3 days before the mixed preparation treatment. However, the effect was somewhat improved.

試験例38〜40は、慢性胃炎と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、2日で完治したのに対し、ゼオライト単独製剤は混合製剤処置11日前から7日間処置したが無効、セリサイト単独製剤は混合製剤処置4日前から4日間処置したがやや改善程度という効果であった。 Test Examples 38 to 40 are volunteers diagnosed with chronic gastritis, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 2 days, whereas the zeolite single preparation was treated for 7 days from 11 days before the mixed preparation treatment, but the sericite single preparation was treated for 4 days from 4 days before the mixed preparation treatment. It was the effect of improvement.

試験例41〜43は、歯周病と診断されたボランテイアであり、製剤例2−1の練状製剤を歯周炎症部に塗り、同時に上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、1日で完治したのに対し、ゼオライト単独製剤は混合製剤処置8日前から5日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置3日前から3日間処置したがやや改善程度という効果であった。   Test Examples 41 to 43 are volunteers diagnosed with periodontal disease, and the paste preparation of Preparation Example 2-1 was applied to the periodontitis part and simultaneously the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in one day, whereas the zeolite single preparation was treated for 5 days from 8 days before the mixed preparation treatment, but the degree of improvement was slightly, and the sericite single preparation was treated for 3 days from 3 days before the mixed preparation treatment. However, there was a slight improvement.

試験例44〜46は、慢性肝臓病と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、10日で完治したのに対し、ゼオライト単独製剤は混合製剤処置60日前から30日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置30日前から30日間処置したがやや改善程度という効果であった。試験例47は、45歳〜70歳の疲労倦怠感をもつ男性ボランテイアで、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、1〜3日で完治したのに対し、ゼオライト単独製剤は混合製剤処置10〜14日前から5〜7日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置5〜7日前から5〜7日間処置したがやや改善程度という効果であった。試験例48〜50は、花粉症と診断されたボランテイアであり、上記カプセル製剤を経口にて摂取させた。その結果、混合製剤は、10日で完治したのに対し、ゼオライト単独製剤は混合製剤処置60日前から30日間処置したがやや改善程度、セリサイト単独製剤は混合製剤処置30日前から30日間処置したが無効という効果であった。   Test Examples 44 to 46 are volunteers diagnosed with chronic liver disease, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 10 days, whereas the zeolite single preparation was treated for 30 days from 60 days before the mixed preparation treatment, but the degree of improvement was slightly improved, and the sericite single preparation was treated for 30 days from 30 days before the mixed preparation treatment. However, there was a slight improvement. Test Example 47 was a male volunteer with fatigue fatigue from 45 to 70 years old, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 1 to 3 days, whereas the zeolite single preparation was treated for 5 to 7 days from 10 to 14 days before the mixed preparation treatment, but the degree of improvement was slightly, and the sericite single preparation was treated with the mixed preparation 5 Although the treatment was carried out for 5 to 7 days from 7 days before, the effect was slightly improved. Test Examples 48 to 50 were volunteers diagnosed with hay fever, and the capsule preparation was taken orally. As a result, the mixed preparation was completely cured in 10 days, whereas the zeolite single preparation was treated for 30 days from 60 days before the mixed preparation treatment, but the degree of improvement was slightly improved, and the sericite single preparation was treated for 30 days from 30 days before the mixed preparation treatment. Was an invalid effect.

経口用カプセル製剤について、ゼオライトとセリサイトの配合比を、90:10〜50:50で変更し、例えば90:10、75:25で配合し、効果の検討をしたが略同一の結果であり、ゼオライトが必須の主成分となることを確認した。   Regarding the oral capsule preparation, the mixing ratio of zeolite and sericite was changed from 90:10 to 50:50, for example 90:10, 75:25, and the effect was examined, but the results were almost the same. It was confirmed that zeolite was an essential main component.

実験例2
エステレーザーによる脱毛処置によって、全身やけど状態になったボランテイアに、次の日より、患部に製剤例2−1の練状製剤を塗りこんだ。製剤は、1日に一度交換追加した。1週間後の写真と処置前の写真を得た(図1、2、3)。処置により、やけどは明確に改善した。
Experimental example 2
From the next day, the kneaded preparation of Formulation Example 2-1 was applied to the volunteers who had become burned by esthetic laser hair removal treatment. The formulation was replaced once a day. A photograph after one week and a photograph before treatment were obtained (FIGS. 1, 2, and 3). The treatment improved the burn clearly.

実験例3
軽度の火傷でひりひり感のあるボランテイアにオロナイン(登録商標)軟膏を患部に塗布した場合、ひりひり感の痛みは3日目にとれ、完治するのに10日を要した。同レベルの火傷ボランテイアに、実施例2−6の練状製剤を患部に塗布した場合、ひりひり感の痛みは1時間でとれ、3日で完治した。
Experimental example 3
When Oronaine (registered trademark) ointment was applied to the affected area on a volunteer with mild burns and tingling, the tingling pain took on the third day and took 10 days to complete. When the kneaded preparation of Example 2-6 was applied to the affected area to the same level of burn volunteers, the pain of irritation was removed in 1 hour and was completely cured in 3 days.

実験例4
肉離れをおこしたボランテイアに市販湿布薬を患部に貼付した場合、痛みは少しやわらぐがなくならず、完治するのに10日を要した。同レベルの肉離れボランテイアに、実施例2−6の練状製剤を患部に塗布した場合、痛みは1時間以内でとれ、3日で完治した。
Experimental Example 4
When a commercially available poultice was applied to the affected part of the volunteer who had left the flesh, the pain did not go away a little, and it took 10 days to recover completely. When the kneaded preparation of Example 2-6 was applied to the affected area at the same level of meat removal volunteers, the pain took within 1 hour and was completely cured in 3 days.

実験例5
胆癌のボランテイアに実施例2−6の練状製剤を胸からわき腹にかけて塗布したところ、痛みは1時間以内でとれた。
Experimental Example 5
When the paste-like preparation of Example 2-6 was applied from the chest to the side of the abdomen, the pain was removed within 1 hour.

実験例6
高純度ゼオライト(表5)と最大粒子径20μm平均粒子径が2μmであるセリサイト(斐川礦業(株)製、斐川マイカZ20)の同重量混合物と水を混合(混合物50mgあたり水を100g添加し、混合液をえる)し混合液を得、経口摂取用水溶液製剤を調製し、これを肺癌末期のボランテイアが、約2ヶ月飲み続けたところ、肺がきれいになり完治した。
Experimental Example 6
Mix the same weight mixture of high purity zeolite (Table 5) and sericite (Yodogawa Mine Co., Ltd., Yodogawa Mica Z20) with a maximum particle size of 20μm and an average particle size of 2μm (add 100g of water per 50mg of the mixture). Then, a liquid mixture was obtained, and an aqueous solution preparation for oral ingestion was prepared. When this was taken by a volunteer at the end of lung cancer for about 2 months, the lungs became clean and completely cured.

本発明の医療用組成物または医療用補助組成物は、各種皮膚疾患等に従来にない効果を発揮し、医療、医療補助、健康食物として極めて有用な新規な組成物を提供する。   The medical composition or medical auxiliary composition of the present invention exhibits an unprecedented effect on various skin diseases and the like, and provides a novel composition that is extremely useful as medical, medical auxiliary, and healthy food.

Claims (4)

ゼオライトとセリサイトを配合してなるアトピー性皮膚炎治療用又は治療補助外用組成物。 A composition for the treatment of atopic dermatitis or external treatment aid, comprising zeolite and sericite. ゼオライトとセリサイトを配合してなるやけど治療用又は治療補助外用組成物。 A composition for the treatment of burns or external treatment aids, comprising zeolite and sericite. ゼオライトとセリサイトを配合してなる染毛による肌の痒み・湿疹の治療用又は治療補助外用組成物。 A composition for the treatment of skin itch / eczema by hair dyeing comprising zeolitic and sericite, or an external treatment aid. ゼオライトとセリサイトを配合してなる陰部・陰部股の痒み・ただれ・痛みの治療用又は治療補助外用組成物。 Treatment or therapeutic auxiliary external composition of itching, sores, pain in the genital-genital crotch formed by blending the zeolite and sericite.
JP2011522827A 2009-07-17 2010-07-14 Medical or medical auxiliary composition comprising zeolite and sericite Expired - Fee Related JP5759894B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011522827A JP5759894B2 (en) 2009-07-17 2010-07-14 Medical or medical auxiliary composition comprising zeolite and sericite

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2009168531 2009-07-17
JP2009168531 2009-07-17
JP2009235118 2009-10-09
JP2009235118 2009-10-09
JP2009270208 2009-11-27
JP2009270208 2009-11-27
JP2011522827A JP5759894B2 (en) 2009-07-17 2010-07-14 Medical or medical auxiliary composition comprising zeolite and sericite
PCT/JP2010/061879 WO2011007794A1 (en) 2009-07-17 2010-07-14 Zeolite and sericite-containing composition for medical or medical assisting uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015048046A Division JP2015143242A (en) 2009-07-17 2015-03-11 Zeolite and sericite-containing composition for medical or medical assisting uses

Publications (2)

Publication Number Publication Date
JPWO2011007794A1 JPWO2011007794A1 (en) 2012-12-27
JP5759894B2 true JP5759894B2 (en) 2015-08-05

Family

ID=43449401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011522827A Expired - Fee Related JP5759894B2 (en) 2009-07-17 2010-07-14 Medical or medical auxiliary composition comprising zeolite and sericite
JP2015048046A Pending JP2015143242A (en) 2009-07-17 2015-03-11 Zeolite and sericite-containing composition for medical or medical assisting uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015048046A Pending JP2015143242A (en) 2009-07-17 2015-03-11 Zeolite and sericite-containing composition for medical or medical assisting uses

Country Status (2)

Country Link
JP (2) JP5759894B2 (en)
WO (1) WO2011007794A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2609926T3 (en) 2011-12-30 2014-01-06 Jakob Hraschan Prevention or treatment of painful polyneuropathies by administering an aluminum silicate
US20160375078A1 (en) 2015-06-24 2016-12-29 Amphora Holdings, Inc. Topical composition comprising natural ingredients for bruising or hematoma healing on skin and use thereof
ES2744718T3 (en) 2016-12-02 2020-02-26 Jakob Hraschan Zeolite compositions and production process thereof
JP6890798B2 (en) * 2017-04-07 2021-06-18 国立大学法人 東京大学 Composition for prevention or treatment of inflammatory bowel disease
CN113038935A (en) * 2018-10-10 2021-06-25 霍利斯特公司 Ostomy powder containing skin healing ingredients
FR3096896A1 (en) * 2019-06-07 2020-12-11 Di Visco NEW COMPOSITION FOR HAIR COLORATION

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003137731A (en) * 2001-11-02 2003-05-14 Naris Cosmetics Co Ltd Antimicrobial powder cosmetic and method for producing antimicrobial powder cosmetic
JP2003267792A (en) * 2002-03-14 2003-09-25 Park Yong-Jin Multipurpose miracle new mineral stone powder and method for producing the same
JP2003290269A (en) * 2002-04-04 2003-10-14 Toya Seishi Kk Supporter and composition for supporter
JP2004149434A (en) * 2002-10-29 2004-05-27 Shiseido Co Ltd Antiperspirant aerosol cosmetic
JP2004307375A (en) * 2003-04-04 2004-11-04 Shiseido Co Ltd Skin care preparation for external use
JP2005119936A (en) * 2003-10-17 2005-05-12 Shunichi Honma Method for producing ceramic by applying microorganism and plant, and minus ion forming material obtained by using the ceramic
JP2005144431A (en) * 2003-11-17 2005-06-09 Aqua Ceramics Corp Functional ceramic particle colloid, producing method of functional ceramic particle colloid, and product produced by using functional ceramic particle colloid
JP2006001873A (en) * 2004-06-17 2006-01-05 Pola Chem Ind Inc Makeup cosmetic
JP2009027957A (en) * 2007-07-26 2009-02-12 Nanasawa Kenkyusho:Kk Soft drink for internal purification, and method for producing the same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003137731A (en) * 2001-11-02 2003-05-14 Naris Cosmetics Co Ltd Antimicrobial powder cosmetic and method for producing antimicrobial powder cosmetic
JP2003267792A (en) * 2002-03-14 2003-09-25 Park Yong-Jin Multipurpose miracle new mineral stone powder and method for producing the same
JP2003290269A (en) * 2002-04-04 2003-10-14 Toya Seishi Kk Supporter and composition for supporter
JP2004149434A (en) * 2002-10-29 2004-05-27 Shiseido Co Ltd Antiperspirant aerosol cosmetic
JP2004307375A (en) * 2003-04-04 2004-11-04 Shiseido Co Ltd Skin care preparation for external use
JP2005119936A (en) * 2003-10-17 2005-05-12 Shunichi Honma Method for producing ceramic by applying microorganism and plant, and minus ion forming material obtained by using the ceramic
JP2005144431A (en) * 2003-11-17 2005-06-09 Aqua Ceramics Corp Functional ceramic particle colloid, producing method of functional ceramic particle colloid, and product produced by using functional ceramic particle colloid
JP2006001873A (en) * 2004-06-17 2006-01-05 Pola Chem Ind Inc Makeup cosmetic
JP2009027957A (en) * 2007-07-26 2009-02-12 Nanasawa Kenkyusho:Kk Soft drink for internal purification, and method for producing the same

Also Published As

Publication number Publication date
JP2015143242A (en) 2015-08-06
JPWO2011007794A1 (en) 2012-12-27
WO2011007794A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
JP2015143242A (en) Zeolite and sericite-containing composition for medical or medical assisting uses
AU2008317965B2 (en) Osmolyte-containing preparation for use in case of dry mucous membranes
JPH0227321B2 (en)
CN105107007B (en) A kind of medical protective dressing of cation and preparation method thereof
CA2732340C (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
JPS58500897A (en) Treatment method and composition for acne
WO2006038802A1 (en) Stabilised oxygen releasing composition
DE102017010930A1 (en) Topical preparations
JP2002515413A (en) Deodorant
CA3189381A1 (en) Make-up remover wipe formulations
FR2662078A1 (en) Cosmetological composition based on a mixture of powdered clay and powdered plants
JP3899267B2 (en) Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders
US11298393B2 (en) Composition comprising a mixture of an extract and bentonite
JPS63230624A (en) Bath liquid
JPS58198421A (en) Composition for decoloring skin and treating skin disease
RU2712085C1 (en) Oral care means
KR20180110357A (en) Cosmetic composition for preventing oxidative stress comprising nephrite water and nephrite powder
WO2012004782A2 (en) Oral remedial mineral replenishment (omr) preparation
KR101548254B1 (en) Composition for treating skin disease comprising sulfur, alum and vinegar
US321839A (en) Stanley w
TW201806602A (en) Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine
TW202042832A (en) Ampelopsis delavayana formula including an ampelopsis delavayana extract, a peppermint extract, a lemon extract and an aloe vera extract
JPH1129486A (en) Skim improver
US8486424B1 (en) Method of preparing a skin treatment composition
KR100290256B1 (en) Use of Benzimidazole Derivative for Hair Tonic

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150608

R150 Certificate of patent or registration of utility model

Ref document number: 5759894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees